Introduction {#s1}
============

Every nervous system is equipped with distinct neuron types essential for different behaviors. Fundamental to nervous system function is the precise establishment and maintenance of neuron type-specific gene expression programs. Integral components of such programs are effector genes that encode proteins critical for neuronal function (e.g., neurotransmitter \[NT\] biosynthesis components, ion channels, NT receptors, neuropeptides) ([@bib17]; [@bib27]; [@bib28]; [@bib29]). These effector genes, referred to as terminal identity genes herein, are expressed continuously, from development throughout life, in post-mitotic neurons in a combinatorial fashion ([@bib27]). Hence, it is the unique overlap of many effector gene products in a specific neuron type that determines its distinct terminal identity, and thereby function. However, the molecular mechanisms that select, in individual neuron types, which terminal identity genes should be expressed and which ones should be repressed are poorly defined. Understanding how neuron type-specific batteries of terminal identity genes are established during development and, perhaps most importantly, maintained throughout life represents one key step towards understanding how individual neuron types become and remain functional. Providing molecular insights into this fundamental problem may also have important biomedical implications, as defects in terminal identity gene expression are associated with a variety of neurodevelopmental and neurodegenerative disorders ([@bib17]; [@bib72]; [@bib33]; [@bib70]).

Seminal genetic studies in multiple model systems revealed a widely employed molecular principle: neuron type-specific transcription factors (TFs) often coordinate the expression of 'desired' terminal identity genes with the exclusion of 'unwanted' terminal identity genes ([@bib52]; [@bib65]; [@bib9]; [@bib13]; [@bib37]; [@bib47]; [@bib49]; [@bib54]). These TFs exert a dual role: they are not only required to induce a specific set of terminal identity features critical for the function of a given neuron type, but also to simultaneously prevent expression of molecular features normally reserved for other neuron types. Consequently, neurons lacking these TFs fail to acquire their unique terminal identity, and concomitantly gain features indicative of alternative identities. For example, mouse striatal cholinergic interneurons lacking *Lhx7* lose their terminal identity and acquire molecular features indicative of GABAergic interneuron identity ([@bib47]). In midbrain neurons, removal of *Gata2* results in loss of GABAergic identity and simultaneous gain of terminal identity features specific to glutamatergic neurons ([@bib37]). However, the molecular mechanisms underlying the dual function of most neuron type-specific TFs remain poorly defined. How can the same TF, within the same cell, promote a specific identity and simultaneously prevent molecular features of alternative neuronal identities? In principle, the same TF can simultaneously operate as direct activator of neuron type-specific terminal identity genes and direct repressor of alternative identity genes ([@bib46]; [@bib85]). Another possibility is indirect regulation. For example, a neuron type-specific TF can prevent adoption of alternative identity features by repressing expression of an intermediary TF that normally promotes such features ([@bib13]). Other mechanisms involving TF competition for cell type-specific enhancers or cell type-specific TF-TF interactions have also been described (see Discussion) ([@bib2]; [@bib24]; [@bib64]; [@bib78]). It remains unclear, however, whether these mechanisms of action of neuron type-specific TFs are broadly applicable in the nervous system.

Although the aforementioned studies begin to explain how neurons select their terminal identity features during development ([@bib52]; [@bib65]; [@bib9]; [@bib13]; [@bib37]; [@bib47]; [@bib49]; [@bib54]), the function of neuron type-specific TFs is rarely assessed during post-embryonic stages. Hence, the molecular mechanisms that maintain neuronal terminal identity features, and thereby neuronal function, are largely unknown. Is the same neuron type-specific TF continuously required, from development through adulthood, to induce a specific set of terminal identity genes and simultaneously prevent 'unwanted' features? Alternatively, a given neuron type could employ different mechanisms for selection (during development) and maintenance (through adulthood) of its function-defining terminal features. Addressing this fundamental problem has been challenging in the vertebrate nervous system, in part due to its inherent complexity and difficulty to track individual neuron types with single-cell resolution from embryo to adult.

To study how neurons select and maintain their terminal identity features, we use as a model the well-defined motor neuron (MN) subtypes of the *Caenorhabditis elegans* ventral nerve cord (equivalent to vertebrate spinal cord). Five cholinergic (DA, DB, VA, VB, AS) and two GABAergic (DD, VD) MN subtypes are located along the nerve cord and control locomotion ([Figure 1A](#fig1){ref-type="fig"}) ([@bib80]; [@bib83]). Because they are present in both *C. elegans* sexes (males and hermaphrodites), we will refer to them as 'sex-shared' MNs. In addition, there are two subtypes of 'sex-specific' cholinergic MNs: the hermaphrodite-specific VC neurons control egg laying ([@bib60]; [@bib67]), and the male-specific CA neurons are required for mating ([@bib69]) ([Figure 1A](#fig1){ref-type="fig"}). In addition to distinct morphology and connectivity, each subtype can be molecularly defined by the combinatorial expression of known terminal identity genes, such as ion channels, NT receptors, and neuropeptides ([Figure 1B](#fig1){ref-type="fig"}). An extensive collection of transgenic reporter *C. elegans* animals for MN subtype-specific terminal identity genes is available, thereby providing a unique opportunity to investigate, at single-cell resolution, the effects of TF gene removal on developing and adult MNs.

![An extensive collection of terminal identity markers for distinct motor neuron subtypes of the *C.*\
*elegans* ventral nerve cord. (**A**) Schematic showing distinct morphology for each motor neuron subtype in the *C. elegans* hermaphrodite. Below, colored dots represent the invariant cell body position of all MNs of the ventral nerve cord (VNC). Red: 39 sex-shared cholinergic MNs (DA2−7 = 6 neurons, DB3−7 = 5, VA2−11 = 10, VB3−11 = 9, AS2−10 = 9); Green: six hermaphrodite-specific VC MNs; Yellow: four sex-shared GABAergic DD neurons (DD2−5 = 4); Blue: nine sex-shared GABAergic VD neurons (VD3−11 = 9). With the exception of VC, all other subtypes have 1--3 extra neurons located at the flanking ganglia (retrovesicular and pre-anal) of the VNC (not shown). Individual neurons of each subtype intermingle along the VNC. (**B**) Table summarizing expression of terminal identity markers for VNC MNs. The sex-shared GABAergic MNs (DD, VD) and the sex-specific MNs (VC, CA) do not express UNC-3. Conversely, the sex-shared cholinergic MNs (DA, DB, VA, VB, AS) and the sex-specific MNs (VC, CA) do not express UNC-30/Pitx. For the genes indicated with an asterisk (\*), a detailed expression pattern is provided in [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}. Of note, the male-specific MNs of the CP subtype are also not shown. (**C**) Schematic that summarizes the known function of UNC-3 (activator of cholinergic MN identity genes) and the question under investigation: does UNC-3 prevent expression of terminal identity features reserved for other MN subtypes?.](elife-50065-fig1){#fig1}

UNC-3, the sole *C. elegans* ortholog of the Collier/Olf/Ebf (COE) family of TFs, is selectively expressed in all sex-shared cholinergic MNs of the nerve cord ([Figure 1B](#fig1){ref-type="fig"}) ([@bib43]; [@bib42]; [@bib56]; [@bib63]; [@bib62]). Animals lacking *unc-3* display striking locomotion defects ([@bib8]). UNC-3 is known to directly activate a large battery of terminal identity genes expressed either in all sex-shared cholinergic MNs (e.g., the NT identity genes *unc-17/* VAChT and *cha-1/* ChAT), or in certain subtypes (e.g., ion channels, NT receptors, signaling molecules) ([@bib42]) ([Figure 1B--C](#fig1){ref-type="fig"}). Based on its ability to broadly co-regulate many distinct terminal identity features, *unc-3* has been classified as a terminal selector gene ([@bib27]). Besides its well-established function as activator of terminal identity genes in cholinergic MNs, whether and how UNC-3 can prevent expression of terminal features of alternative neuronal identities remains unclear.

Here, we describe a dual role for UNC-3 that enables sex-shared cholinergic MNs to select during development and maintain throughout life their terminal identity features. We find that UNC-3 is continuously required - from development through adulthood - not only to activate cholinergic MN identity genes, but also to prevent expression of terminal features normally reserved for other MN subtypes of the nerve cord, namely the sex-shared GABAergic VD neurons and sex-specific cholinergic MNs (CA, VC). These findings lend support to the notion that neuron type-specific TFs can promote a specific identity and simultaneously suppress features reserved for alternative, but functionally related, neuronal identities.

To uncover the molecular mechanism underlying the dual role of UNC-3, we conducted an unbiased genetic screen, which led to the identification of the Hox protein LIN-39 (Scr/Dfd/Hox4-5) as the intermediary factor necessary for expression of alternative neuronal identity features (e.g., VD, VC) in *unc-3*-depleted MNs. Unlike previously described cases of TFs that act indirectly to prevent alternative neuronal identities by repressing intermediary factors (discussed earlier), UNC-3 does not repress *lin-39* and both factors are co-expressed in cholinergic MNs. However, UNC-3 antagonizes the ability of LIN-39 to induce terminal features of alternative identities. Intriguingly, UNC-3 also synergizes with LIN-39 to co-activate multiple terminal identity features specific to cholinergic MNs. Consequently, loss of *unc-3* causes a switch in the transcriptional targets of LIN-39, thereby alternative, not cholinergic MN-specific, terminal identity features become activated and locomotion defects occur. Given that terminal selectors and Hox proteins are expressed in a multitude of neuron types across species ([@bib17]; [@bib30]; [@bib58]; [@bib22]), the strategy of a terminal selector preventing a Hox transcriptional switch may constitute a general principle for safeguarding neuronal identity throughout life.

Results {#s2}
=======

UNC-3 has a dual role in distinct populations of ventral nerve cord (VNC) motor neurons {#s2-1}
---------------------------------------------------------------------------------------

Neuron type-specific TFs often promote a specific identity and simultaneously suppress features reserved for other, functionally related neuronal types ([@bib4]). To test this notion for UNC-3, it was essential to identify a set of terminal identity markers for all *unc-3*-negative MN subtypes of the VNC, namely the GABAergic (VD, DD) and sex-specific (VC, CA) MNs ([Figure 1B](#fig1){ref-type="fig"}). We undertook a candidate gene approach and examined the precise expression pattern of terminal identity genes (e.g., NT receptors, signaling proteins, ion channels, neuropeptides) reported to be expressed in *unc-3*-negative MNs ([www.wormbase.org](http://www.wormbase.org)). In total, we carefully characterized at single-cell resolution the expression of 15 genes in wild-type animals of both *C. elegans* sexes at the fourth larval stage (L4) (see Materials and methods and [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). This analysis provided nine terminal identity markers highly specific to *unc-3*-negative MNs that fall into four categories ([Figure 1B](#fig1){ref-type="fig"}): (a) two VD-specific markers (*ser-2*/serotonin receptor \[ortholog of HTR1D\]*; oig-1/* one Ig domain protein), (b) one DD-specific marker (*flp-13/* FMRF like neuropeptide), (c) three markers for sex-specific (VC in hermaphrodites, CA in males) MNs (*glr-5*/glutamate receptor \[ortholog of GRID/GRIK\]; *srb-16*/serpentine GPCR receptor; *ida-1*/ortholog of protein tyrosine phosphatase PTPRN), and (**d**) three markers expressed in both GABAergic subtypes (DD, VD) and sex-specific MNs (*flp-11*/FRMR like neuropeptide*, twk-46*/potassium channel \[ortholog of KCNK1\]*, ilys-4/* invertebrate type lysozyme).

These nine markers enabled us to test whether *unc-3-*depleted MNs gain expression of terminal features normally reserved for other MN subtypes. By using animals carrying a strong loss-of-function (null) allele for *unc-3 (n3435)* ([@bib63]), we first assessed any putative effects on terminal markers for the sex-shared GABAergic MNs (DD, VD). Although the DD-specific marker *flp-13* is unaffected ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}, panel **A**), ectopic expression of the VD-specific markers (*ser-2, oig-1*) was observed in *unc-3*-depleted MNs ([Figure 2A--B](#fig2){ref-type="fig"}). Interestingly, this ectopic expression was region-specific, observed in cholinergic MNs of the mid-body region of the VNC with 100% penetrance ([Figure 2A--B](#fig2){ref-type="fig"}). Importantly, 12.1 ± 2.6 (mean ± STDV) out of the 39 *unc-3*-depleted MNs in the VNC were ectopically expressing these VD markers, suggesting that not all *unc-3-*depleted MNs acquire VD terminal identity features. Given that GABAergic and cholinergic MNs are generated in normal numbers in *unc-3* animals ([@bib42]), the increase in the number of neurons expressing the VD markers cannot be attributed to early developmental defects affecting MN numbers. We next asked whether these \~12 MNs adopt additional VD terminal identity features, such as expression of genes involved in GABA biosynthesis (*unc-25/GAD* and *unc-47/VGAT)*, or selectively expressed in GABAergic MNs (*ttr-39, klp-4*). However, this does not appear to be the case, arguing against a complete cell fate switch ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}, panel A). We conclude that, in the absence of *unc-3,* cholinergic MNs not only lose their original terminal identity, but a third of them (\~12 out of 39) in the mid-body VNC region also gain some terminal identity features normally reserved for the sex-shared VD neurons ([Figure 1](#fig1){ref-type="fig"}). We will refer to these *unc-3*-depleted MNs as 'VD-like' ([Figure 2G](#fig2){ref-type="fig"}). We also uncovered the identity of these cells across multiple *unc-3* mutant animals and conclude that it is the same 12 neurons that become VD-like across animals ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}, panel B).

![UNC-3 has a dual role in cholinergic ventral cord motor neurons.\
(**A**) Terminal identity markers of VD neurons (*ser-2, oig-1*) are ectopically expressed in *unc-3*-depleted MNs. Representative images of larval stage 4 (L4) hermaphrodites are shown. Similar results were obtained in adult animals. Arrowheads point to MN cell bodies with *gfp* marker expression. Green fluorescence signal is shown in white for better contrast. Dotted black box indicates imaged area. (**B**) Quantification of VD markers (*ser-2, oig-1*) in WT and *unc-3 (n3435)* at L4. N \> 15. \*\*\*p\<0.001. For details on box plots, see Materials and methods. (**C**) Terminal identity markers of VC neurons (*ida-1, srb-16, glr-5*) are ectopically expressed in *unc-3*-depleted MNs. Representative images of larval stage 4 (L4) hermaphrodites are shown. Similar results were obtained in adult animals. Arrowheads point to MN cell bodies with *gfp* marker expression. Green fluorescence signal is shown in white for better contrast. Dotted black box indicates imaged area. (**D**): Quantification of VC markers (*ida-1, srb-16, glr-5*) in WT and *unc-3 (n3435)* at L4. Individual data points are dot-plotted. N \> 15. \*\*\*p\<0.001. (**E**) Distinct MNs acquire VC-like or VD-like terminal identity features in *unc-3 (n3435)* mutants. The VC marker in green (*ida-1::gfp*) and the VD marker in red (*ser-2::rfp*) do not co-localize in WT or *unc-3 (n3435)* mutants. Representative images are shown. Individual VC/VC-like and VD/VD-like neurons are pointed and circled, respectively,(VD: dotted circles; VC: arrowheads) to highlight that an individual MN never expresses both markers. (**F**) Quantification of data shown in E. N \> 16. (**G**) Schematic that summarizes the dual role of *unc-3*. Apart from activating cholinergic MN terminal identity genes, UNC-3 prevents expression of VD and VC terminal features in distinct cells ('VD-like' versus 'VC-like').](elife-50065-fig2){#fig2}

To test whether UNC-3 also prevents expression of terminal identity features of sex-specific cholinergic MNs, we examined three VC-specific terminal markers (*glr-5, srb-16, ida-1* in [Figure 1B](#fig1){ref-type="fig"}) in hermaphrodite nematodes lacking *unc-3*. Again, we observed region-specific effects with 100% penetrance in the same cells across multiple animals ([Figure 2C--D](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}, panel B). All three markers were ectopically expressed in 10.5 ± 3.7 (mean ± STDV) of the 39 *unc-3*-depleted MNs located in the mid-body region of the VNC ([Figure 2C--D](#fig2){ref-type="fig"}). These results are in agreement with a previous study reporting ectopic *ida-1* expression in *unc-3*-depleted MNs ([@bib63]). If these \~11 MNs fully adopt the VC terminal identity, then they should also express genes necessary for acetylcholine biosynthesis since VC neurons are cholinergic. However, this is not the case as expression of *unc-17*/VAChT and *cho-1*/ChT is dramatically affected in *unc-3*-depleted MNs ([@bib42]). These data suggest that \~11 of the 39 *unc-3*-depleted MNs in the mid-body VNC region adopt some, but not all, VC terminal identity features. We will therefore refer to these *unc-3*-depleted MNs as 'VC-like' ([Figure 2G](#fig2){ref-type="fig"}).

Are the VD-like and VC-like neurons in *unc-3* hermaphrodites distinct populations? To test this, we generated *unc-3* hermaphrodites that carry a green fluorescent reporter for VC terminal identity (*ida-1::gfp*) and a red reporter for VD identity (*ser-2::rfp*). We found no overlap of the two reporters, indicating that the VD-like and VC-like neurons represent two distinct populations ([Figure 2E--F](#fig2){ref-type="fig"}). We further corroborated this result by taking advantage of the invariant lineage and cell body position of all MNs along the *C. elegans* nerve cord ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}, panel B). Of note, the VC-like population appears to be lineally related to VC neurons, whereas the VD-like population is not lineally related to VD neurons ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}, panels B-C). Lastly, terminal identity markers normally expressed in both VD and VC neurons (*flp-11, ilys-4, twk-46*) display an additive effect in *unc-3* mutants, as they are ectopically expressed in both VD-like and VC-like populations, further suggesting the presence of distinct *unc-3* MN populations ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}, panels D-E).

To summarize, there are 39 *unc-3*-expressing MNs along the wild-type nerve cord in hermaphrodites. While loss of *unc-3* uniformly leads to loss of cholinergic identity in all these MNs ([@bib42]), one population (\~12 MNs) acquires VD-like molecular features, while a second population (\~11 MNs) acquires VC-like molecular features, uncovering a dual role of UNC-3 in these populations ([Figure 2G](#fig2){ref-type="fig"}). Of note, the remaining MNs (\~16) in the VNC of *unc-3* mutants \[39 - (12 VD-like + 11 VC-like)=16\] do not gain either VD or VC terminal identity features.

The dual role of UNC-3 in cholinergic MNs extends to both *C. elegans* sexes {#s2-2}
----------------------------------------------------------------------------

To test whether the dual function of UNC-3 applies to both sexes, we extended our analysis to *C. elegans* males. First, we showed that loss of *unc-3* in males resulted in loss of several cholinergic MN terminal identity features ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). Second, we observed ectopic expression of VD-specific terminal identity markers (*oig-1, ser-2*) in 11.9 ± 3.9 (mean ± STDV) out of the 39 *unc-3*-depleted MNs, indicating the presence of 'VD-like' neurons in the male nerve cord ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). Lastly, we asked whether *unc-3* loss leads to ectopic expression of terminal identity markers (*ida-1, srb-16, glr-5*) for male-specific CA neurons. Indeed, we found this to be the case ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}), suggesting the adoption of 'CA-like' features by a population of *unc-3*-depleted MNs. Similar to hermaphrodites, these VD-like and CA-like cells were observed in the mid-body region of the male nerve cord with 100% penetrance ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}).

Taken together, our findings uncover a dual role for UNC-3 in sex-shared cholinergic MNs. UNC-3 is not only required to activate cholinergic MN identity genes ([@bib42]), but also to prevent expression of molecular features normally reserved for three other, functionally related neuronal subtypes of the nerve cord (VD, VC, CA). In both sexes, UNC-3 prevents expression of select terminal features of VD neurons in a specific population of cholinergic MNs. In a second population, UNC-3 prevents expression of terminal features normally reserved for sex-specific MNs, that is VC features in hermaphrodites and CA features in males. In the ensuing sections, we focus our analysis on *C. elegans* hermaphrodites to dissect the molecular mechanism underlying the dual role of UNC-3.

UNC-3 is continuously required to prevent expression of VD and VC terminal identity features {#s2-3}
--------------------------------------------------------------------------------------------

Neuron type-specific TFs that promote a specific identity and simultaneously prevent alternative features have been previously described (see Introduction). However, whether this dual role is required transiently (during development), or continuously (throughout life) remains unclear. The UNC-3 case provides an opportunity to distinguish between these two possibilities because ectopic expression of VC and VD features is observed at both larval and adult stages in *unc-3* null animals ([Figure 2](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). To this end, we employed the auxin-inducible degron (AID) system that enables depletion of UNC-3 in a temporally controlled manner ([@bib88]). This system requires tagging the UNC-3 protein with the AID degron fused to a fluorescent reporter gene (mNeonGreen, mNG). When UNC-3::mNG::AID and the plant-specific F-box protein TIR1 are co-expressed in MNs (by crossing animals carrying the *unc-3::mNG::AID* allele with *eft-3::TIR1* transgenic animals), application of the plant hormone auxin on these double transgenic animals induces degradation of UNC-3::mNG::AID ([Figure 3A--C](#fig3){ref-type="fig"}). Auxin administration at the L4 stage (last larval stage before adulthood) on *unc-3::mNG::AID; eft-3::TIR1* animals resulted in a dramatic depletion of UNC-3 at day one adult animals (24 hr after auxin). UNC-3 depletion was accompanied by ectopic expression of VD and VC terminal identity features in nerve cord MNs, demonstrating a post-embryonic requirement for UNC-3 ([Figure 3D--E](#fig3){ref-type="fig"}). Similar results were obtained when auxin was applied at different time points ([Figure 3D](#fig3){ref-type="fig"}, legend). These findings suggest that UNC-3 is continuously required to prevent expression of VD and VC terminal identity features.

![UNC-3 is continuously required to prevent expression of VD and VC terminal identity features.\
(**A**) Schematic showing time window of auxin administration. (**B**) Animals of the *unc-3::mNG::AID; eft-3::TIR1* genotype were either administered ethanol (EtOH) or auxin at the L4 stage. Twenty four hours later, expression of endogenous *unc-3* reporter (*unc-3::mNG::AID*) is severely reduced in the nuclei of VNC MNs (arrowheads) at the young adult stage (day 1). The same exact region was imaged in EtOH- and auxin-treated worms. mNG green fluorescent signal is shown in white for better contrast. White dotted line indicates the boundary of intestinal tissue (gut), which tends to be autofluorescent in the green channel. (**C**) Quantification of number of MNs expressing the *unc-3::mNG::AID* reporter after EtOH (control) and auxin treatment. N \> 12. \*\*\*p\<0.001. (**D**) Auxin or ethanol (control) were administered at larval stage 3 (L3) on *unc-3::mNG::AID; eft-3::*TIR1 animals carrying the VD marker *ser-2::gfp.* Images were taken at the young adult stage (day 1.5). A significant increase in the number of MNs expressing the VD marker was evident in the auxin-treated animals compared to EtOH-treated controls. For comparison, quantification is provided for *ser-2::gfp* expressing MNs of wild-type animals and *unc-3(n3435)* mutants. Similar results were obtained when auxin was applied at L4 or day 1 adult animals. N \> 20. \*\*\*p\<0.001. (**E**) Auxin or ethanol (control) were administered at larval stage 4 (L4) on *unc-3::mNG::AID; eft-3::*TIR1 animals carrying the VC marker *glr-5::gfp.* Images were taken at the young adult stage (day 2). A significant increase in the number of MNs expressing the VC marker was evident in the auxin-treated animals compared to EtOH-treated controls. N \> 11. \*p\<0.05; \*\*\*p\<0.001.](elife-50065-fig3){#fig3}

UNC-3 acts indirectly to prevent expression of VD and VC terminal identity genes {#s2-4}
--------------------------------------------------------------------------------

How does UNC-3 activate cholinergic MN identity genes and simultaneously prevent terminal features of alternative MN identities (e.g., VD, VC) ([Figure 2G](#fig2){ref-type="fig"})? Based on previous reports, the same TF, within the same neuron, can act as a direct activator for a set of genes and a direct repressor for another set of genes ([@bib46]; [@bib85]; [@bib6]). While it is known that UNC-3 acts directly -- through its cognate binding site (COE motif) -- to activate expression of a large battery of cholinergic MN identity genes, we did not find any COE motifs in the *cis*-regulatory region of VD or VC terminal identity genes ([Supplementary file 1](#supp1){ref-type="supplementary-material"}). This contrasts the previously described function of UNC-3 as direct repressor (through the COE motif) of terminal identity genes in the chemosensory ASI neurons of *C. elegans* ([@bib40]).

To test the possibility of indirect repression via an intermediary factor, we focused on VD neurons because, unlike VC neurons, a known activator of VD terminal features has been reported ([@bib14]; [@bib19]; [@bib36]). In wild-type animals, the TF UNC-30, ortholog of human PITX1-3, is required to induce VD terminal identity genes. Since UNC-30 is not expressed in cholinergic MNs ([@bib36]), we hypothesized that UNC-3 prevents expression of UNC-30/PITX, leading to inactivation of VD terminal identity genes. However, this is not the case because: (1) ectopic *unc-30* expression is not observed in *unc-3*-depleted MNs, and (2) the ectopic expression of the VD marker (*ser-2*) in *unc-3* mutants was not abolished in *unc-3; unc-30* double mutants ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). These observations suggest that UNC-3 may act indirectly to prevent expression of VD and VC terminal identity genes through as yet unknown intermediary factors.

The mid-body Hox protein LIN-39 (Scr/Dfd/Hox4-5) is the intermediary factor necessary for ectopic expression of VD and VC features in *unc-3* mutants {#s2-5}
-----------------------------------------------------------------------------------------------------------------------------------------------------

If the hypothesis of indirect repression is correct, mutation of the intermediary factor(s) in the *unc-3* mutant background would selectively eliminate ectopic expression of VD and/or VC terminal identity genes in *unc-3*-depleted MNs. To identify such factor(s), we embarked on an unbiased genetic screen. For the screen, we chose a transgenic *gfp* reporter strain for *flp-11*, an FMRF-like neuropeptide-encoding gene expressed in both VD and VC neurons ([Figure 1B](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}), which is markedly affected by UNC-3 ([Figure 4A--B](#fig4){ref-type="fig"}, [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}, panels D-E). We mutagenized *unc-3 (n3435); flp-11::gfp* animals with ethyl methanesulfonate (EMS) and visually screened \~4200 haploid genomes for mutants in which ectopic *flp-11::gfp* expression in *unc-3*-depleted MNs is suppressed. We isolated one mutant allele (*kas1*) ([Figure 4A--B](#fig4){ref-type="fig"}). The phenotype was 100% penetrant as all *unc-3 (n3435); flp-11::gfp* animals carrying *kas1* in homozygosity consistently displayed a dramatic reduction in ectopic *flp-11* expression.

![A genetic screen identifies the mid-body Hox protein LIN-39 (Scr/Dfd/Hox4-5) as necessary for ectopic expression of VD and VC terminal features.\
(**A**) Representative images of L4-stage WT, *unc-3(n3435), unc-3(n3435); kas1*, and *unc-3(n3435); lin-39(n1760)* animals carrying *flp-11::gfp* (VD/VC marker). Arrowheads point to MN cell bodies with *gfp* marker expression. (**B**) Quantification graph summarizing results from panel A. The two right-most bars show quantification of two independent transgenic lines driving *lin-39 RNAi* specifically in cholinergic MNs (*Punc-3 \>lin-39 RNAi*) of *unc-3 (n3435)* mutants. N \> 15. \*\*\*p\<0.001. N.S: not significant. (**C**) Genetic locus of *lin-39*. Molecular lesions for *kas1* and *n1760* alleles are shown, as well as the *AID::3xFLAG::mNG* cassette inserted at the C-terminus (endogenous reporter). (**D**) Quantification of two VD (*ser-2::gfp, oig-1::gfp*) and one VC (*ida-1::gfp*) markers in WT, *unc-3 (n3435), unc-3(n3435); lin-39(n1760)* animals at L4. The three right-most bars show quantification of three independent transgenic lines driving *lin-39 RNAi* specifically in cholinergic MNs (*Punc-3 \>lin-39 RNAi*) of *unc-3 (n3435)* mutants. N \> 15. \*\*\*p\<0.001. (**E**) Summary of *unc-3* and *lin-39* expression in cholinergic MNs. See [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"} for raw data. (**F**) Schematic that summarizes our findings. In the wild type ([@bib23]) panel on the left, *lin-39* is normally expressed in cholinergic MNs but unable to induce expression of VD or VC genes. In the *unc-3* mutant, *lin-39* is now able to induce expression of alternative identity features (VD or VC) in distinct MN populations.](elife-50065-fig4){#fig4}

Gross morphological examination of *unc-3 (n3435); kas1; flp-11::gfp* hermaphrodites revealed that, unlike *unc-3 (n3435); flp-11::gfp* animals, the introduction of *kas1* is accompanied by a lack of the vulva organ (vulvaless phenotype). Upon a literature survey for TF mutants that are vulvaless, we stumbled across the mid-body Hox gene *lin-39* (ortholog of Dfd/Scr in flies and Hox4-5 in vertebrates) ([@bib1]; [@bib15]), and hypothesized that the molecular lesion of *kas1* may lie in the *lin-39* locus. Indeed, Sanger sequencing uncovered a point mutation on the splice acceptor site (WT: A[G]{.ul} \> *kas1*: A[A]{.ul}) in the second intron of *lin-39* ([Figure 4C](#fig4){ref-type="fig"}). Similar to *unc-3 (n3435); kas1* animals, *unc-3 (n3435)* mutants carrying a previously published strong loss-of-function (premature STOP) allele of *lin-39 (n1760)* ([@bib15]) displayed the same loss of ectopic *flp-11* expression ([Figure 4A--C](#fig4){ref-type="fig"}), suggesting that *kas1* is a loss-of-function mutation of *lin-39*. The ectopic expression of *flp-11* in *unc-3(n3435); kas1* animals can be, at least partially, rescued by (1) selective expression of *lin-39* cDNA in cholinergic MNs, and (2) introduction of the *lin-39* wild-type locus in the context of a \~ 30 kb genomic clone (fosmid) ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}), corroborating that the *kas1* lesion in the *lin-39* locus is the phenotype-causing mutation.

Because *flp-11* is expressed in both VD and VC neurons, we next tested whether *lin-39* is required for ectopic expression of VD-specific (*ser-2, oig-1*) and VC-specific (*ida-1*) terminal identity genes in *unc-3*-depleted MNs. We found this to be the case by either generating *unc-3 (n3435); lin-39 (n1760)* double mutants (for VD markers) or by performing cholinergic MN-specific RNAi for *lin-39* in *unc-3 (n3435)* animals (for VC marker) ([Figure 4D](#fig4){ref-type="fig"}). RNAi was necessary because VC neurons do not survive in *lin-39 (n1760)* animals ([@bib61]), and the use of the *n1760* allele could confound our VC marker quantifications. Of note, all other nerve cord MN subtypes are normally generated in *lin-39 (n1760)* single and *unc-3 (n3435); lin-39 (n1760)* double mutants ([@bib75]), indicating that suppression of the *unc-3* phenotype, that is, loss of ectopic VD gene expression in the double mutants is not due to MN elimination. Taken together, our genetic screen identified the mid-body Hox gene *lin-39* to be necessary for ectopic expression of both VD and VC terminal features in *unc-3*-depleted MNs ([Figure 4F](#fig4){ref-type="fig"}).

Interestingly, this finding contradicts our initial hypothesis of UNC-3 repressing an intermediary TF in order to prevent expression of VD and VC features because *lin-39* is co-expressed with (not repressed by) *unc-3* in wild-type cholinergic MNs at the mid-body region of the VNC ([Figure 4E](#fig4){ref-type="fig"}), as evident by our single-cell analysis of *unc-3* and *lin-39* reporters ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). Of note, 28 cholinergic MNs co-express *unc-3* and *lin-39*, which is in close agreement with the total number of VD-like (12.1 ± 2.6) and VC-like (10.5 ± 3.7) cells observed in *unc-3* mutants ([Figure 4E--F](#fig4){ref-type="fig"}). Moreover, we found that *lin-39* acts cell-autonomously as cholinergic MN-specific RNAi against *lin-39* in *unc-3 (n3435)* animals resulted in a significant reduction of ectopic terminal identity marker (*flp-11, ida-1)* expression ([Figure 4B--D](#fig4){ref-type="fig"}). In the following Results sections, we describe the molecular mechanism through which UNC-3 and LIN-39/Hox select and maintain throughout life key terminal features of cholinergic MNs ([Figure 4F](#fig4){ref-type="fig"}).

UNC-3 prevents a switch in the transcriptional targets of LIN-39 in cholinergic motor neurons {#s2-6}
---------------------------------------------------------------------------------------------

What is the function of LIN-39 in wild-type cholinergic MNs of the VNC? Our previous findings suggested that LIN-39 and UNC-3, together with another mid-body Hox protein, MAB-5 (Antp/Hox6-8) ([@bib66]), act synergistically to control expression of two cholinergic MN terminal identity genes (*unc-129,* ortholog of human BMP; *del-1*/Degenerin like sodium channel \[ortholog of human SCNN1G\]) ([@bib43]). To test the extent of this synergy, we examined in *lin-39* and *mab-5* null animals the expression of 4 additional cholinergic MN terminal identity genes known to be controlled by UNC-3 (*acr-2/nicotinic acetylcholine receptor; dbl-1/DPP/BMP-like; unc-77/sodium channel \[ortholog of human NALCN\], slo-2/potassium sodium-activated channel \[ortholog of human KCNT1\]*) ([@bib42]). In all four cases, we found a statistically significant decrease in *lin-39* mutants, and this effect was exacerbated in *lin-39; mab-5* double mutants ([Figure 5A--B](#fig5){ref-type="fig"}), indicating that the synergy of LIN-39 with MAB-5 (and UNC-3) extends to multiple terminal identity genes in cholinergic MNs (WT panel in [Figure 5D](#fig5){ref-type="fig"}). The observed effects were 100% penetrant and consistent with the previously described region-specific expression pattern of *lin-39* and *mab-5* in VNC MNs ([Figure 5A](#fig5){ref-type="fig"}) ([@bib43]). Of note, while MAB-5 collaborates with LIN-39 to activate cholinergic MN identity genes ([Figure 5B](#fig5){ref-type="fig"}), it does not affect the ectopic expression of VD or VC genes observed in *unc-3* mutants ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}).

![UNC-3 prevents a switch in the transcriptional targets of LIN-39 in cholinergic motor neurons.\
(**A**) Schematic summarizing the expression pattern of *lin-39* and *mab-5* in VNC cholinergic MNs. Below, representative images are shown of *unc-77::gfp* in *WT, lin-39 (n1760), mab-5 (1239)* and *lin-39 (n1760); mab-5 (1239)* animals at L4 stage. Arrowheads point to MN cell bodies with *gfp* marker expression. Green fluorescence signal is shown in white for better contrast. Dotted black box indicates imaged area. (**B**) Quantification of cholinergic MN terminal identity markers (*unc-77, dbl-1, acr-2, slo-2*) in *WT, lin-39 (n1760), mab-5 (1239)* and *lin-39 (n1760); mab-5 (1239)* animals at L4. N \> 15. \*\*p\<0.01; \*\*\*p\<0.001. (**C**) ChIP-Seq tracks are shown for LIN-39 on four cholinergic MN terminal identity genes (*acr-2, unc-129, dbl-1, del-1*). The WT data come from the modENCODE project ([@bib7]), whereas the *unc-3 (-)* data were obtained by performing ChIP-Seq for LIN-39 on *unc-3 (n3435); lin-39 (kas9 \[lin-39::mNG::3xFLAG::AID\]* animals. (**D**) Schematic showing the transcriptional switch in LIN-39 targets. In WT animals, UNC-3, MAB-5 and LIN-39 co-activate subtype-specific genes in cholinergic MNs (e.g., *unc-77, dbl-1, unc-129, acr-2*). In *unc-3* mutants, LIN-39 is no longer able to activate these genes, and instead switches to VD- or VC-specific terminal identity genes. Black font: gene expressed. Gray font: gene not expressed. Gray arrows indicate inactive genetic interactions. COE motif taken from [@bib42] and LIN-39 site taken from [@bib82] are represented with black rectangles and dots, respectively.](elife-50065-fig5){#fig5}

Since UNC-3 controls directly, via its cognate binding site, cholinergic MN terminal identity genes ([@bib42]), we then asked whether this is the case for LIN-39. We analyzed available ChIP-Seq data for LIN-39 from the modENCODE project ([@bib7]) and found evidence for direct LIN-39 binding in the *cis*-regulatory of all six cholinergic MN terminal identity genes (*unc-129, del-1, acr-2, dbl-1, unc-77, slo-2*) ([Figure 5C](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Moreover, we identified multiple consensus LIN-39 binding sites (previously defined as GATTGATG) ([@bib7]) located within the LIN-39 ChIP-Seq peaks in the *cis*-regulatory region of the aforementioned genes ([Supplementary file 2](#supp2){ref-type="supplementary-material"}).

This analysis strongly suggests that LIN-39, similar to UNC-3, regulates directly the expression of multiple terminal identity genes in cholinergic MNs ([Figure 5D](#fig5){ref-type="fig"}). However, in the absence of UNC-3, the function of LIN-39 in cholinergic MNs is modified. Instead of activating cholinergic MN identity genes, LIN-39 activates VD or VC terminal identity genes in *unc-3*-depleted MNs ([Figure 4](#fig4){ref-type="fig"}). Taken together, our data suggest that UNC-3 antagonizes the ability of LIN-39 to activate alternative identity genes, thereby preventing a switch in the transcriptional targets of LIN-39 (model schematized in [Figure 5D](#fig5){ref-type="fig"}). If this hypothesis is correct, one would expect decreased LIN-39 binding in the *cis*-regulatory region of cholinergic MN terminal identity genes in *unc-3* mutants. By performing ChIP-Seq for LIN-39 in *unc-3* mutant animals, we indeed observed decreased LIN-39 binding in the *cis*-regulatory region of the aforementioned genes ([Figure 5C](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). As a positive control, LIN-39 binding in *unc-3* mutant animals was observed in other loci, including the *lin-39* locus itself ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}), consistent with the known role of LIN-39 in regulating its own expression ([@bib55]). Similar results were obtained by ChIP-qPCR for LIN-39 targets in *unc-3* mutants animals ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). We conclude that, in the absence of UNC-3, LIN-39 is released from cholinergic MN terminal identity gene promoters, presumably leading to increased availability of LIN-39 and thereby activation of alternative identity genes.

LIN-39 is continuously required to control expression of terminal identity genes in cholinergic MNs {#s2-7}
---------------------------------------------------------------------------------------------------

The neuronal function of Hox proteins at post-developmental stages is largely unknown ([@bib32]). The continuous expression of mid-body Hox *lin-39* in both developing and adult cholinergic MNs led us to investigate whether *lin-39* is required to maintain expression of terminal identity genes in these neurons. To test this idea, we employed clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9-based genome engineering and generated an auxin-inducible *lin-39* allele (*lin-39::mNG::3xFLAG::AID*) that also serves as an endogenous *lin-39* reporter (*mNG*). Animals carrying *lin-39::mNG::3xFLAG::*AID display no developmental phenotypes and show nuclear mNG expression in MNs located at the mid-body region of the VNC during development and adult stages ([Figure 6A](#fig6){ref-type="fig"}), corroborating previous observations with a LIN-39 antibody ([@bib48]). Upon crossing the *lin-39::mNG::3xFLAG::AID* animals with the *eft-3::TIR1* line, we observed hypomorphic effects in the expression of two cholinergic MN identity genes (*acr-2*, *unc-77)* ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}, panel C). Although LIN-39 protein is present in the nuclei of cholinergic MNs of *lin-39::mNG::3xFLAG::AID; eft-3::TIR1* animals ([Figure 6A](#fig6){ref-type="fig"}), these effects are likely due to a mild reduction in LIN-39 levels triggered by TIR1. However, post-embryonic auxin administration on these animals resulted in efficient LIN-39 protein depletion and significantly enhanced these effects ([Figure 6A--C](#fig6){ref-type="fig"}, [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}, panel C). We therefore conclude that LIN-39 is continuously required to maintain terminal identity features in cholinergic MNs.

![LIN-39 is continuously required to control expression of terminal identity genes.\
(**A**) Animals of the *lin-39::mNG::3xFLAG::AID; eft-3::TIR1* genotype were either administered ethanol (EtOH) or auxin at the L3 stage. Twenty four hours later, expression of endogenous *lin-39* reporter (*lin-39::mNG::3xFLAG::AID*) is severely reduced in the nuclei of VNC MNs (arrowheads) at the young adult stage (day 1). mNG green fluorescent signal is shown in white for better contrast. White dotted line indicates the boundary of intestinal tissue (gut), which tends to be autofluorescent in the green channel. (**B**) Quantification of number of MNs expressing the *lin-39::mNG::3xFLAG::AID* reporter after EtOH (control) and auxin treatment. N \> 14. \*\*\*p\<0.001. (**C**) Schematic showing time window of auxin administration. (**D--F**) Auxin or ethanol (control) were administered at larval stage 4 (L4) on *unc-3 (n3435); lin-39::mNG::3xFLAG::AID; eft-3::TIR1* animals carrying either the VD marker *ser-2::gfp,* the VC marker *glr-5::gfp,* or the VD/VC marker *flp-11::gfp.* Images were taken at the young adult stage (day 1.6 for *ser-2*, day 1.8 for *glr-5* and day two for *flp-11*). A significant decrease in the number of MNs expressing the VD marker was evident in the auxin-treated animals compared to EtOH-treated controls. For comparison, quantification of marker expression is also provided in *unc-3 (n3435)* mutants. We note that hypomorphic effects in the ethanol treated group have been previously reported for other AID-tagged TFs in *C. elegans* ([@bib39]). Such effects appear to be target gene-specific, as they were observed for *glr-5* and *flp-11*, but not *ser-2* ([Figure 6E--F](#fig6){ref-type="fig"}). N \> 15. \*\*p\<0.01, \*\*\*p\<0.001, N. S: not significant.](elife-50065-fig6){#fig6}

Next, we sought to determine whether LIN-39 is continuously required for the ectopic activation of VD and VC terminal features observed in *unc-3* null animals. Indeed, auxin administration at L4 stage on *unc-3(n3435); lin-39::mNG::3xFLAG::AID* animals carrying either a VD (*ser-2*), VC (*glr-5*), or VD/VC (*flp-11*) marker resulted in a statistically significant suppression of the *unc-3* phenotype when compared to control (treated with ethanol) ([Figure 6D--F](#fig6){ref-type="fig"}).

To sum up, our findings with the auxin-inducible ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}, panel C) and null *lin-39* alleles ([Figures 4F](#fig4){ref-type="fig"} and [5A--B](#fig5){ref-type="fig"}) indicate that, in the presence of UNC-3, LIN-39 is required to induce and maintain expression of cholinergic MN terminal identity genes ([Figure 5D](#fig5){ref-type="fig"}). In the absence of UNC-3 ([Figure 6](#fig6){ref-type="fig"}), LIN-39 is also continuously required - from development and possibly throughout life - for ectopic activation of VD and VC terminal identity genes ([Figure 5D](#fig5){ref-type="fig"}).

LIN-39 is an activator of VD and VC terminal identity genes {#s2-8}
-----------------------------------------------------------

The observation that *lin-39* is required for ectopic activation of both VD and VC terminal identity genes in *unc-3*-depleted MNs prompted us to examine the role of *lin-39* in VD and VC neurons of wild-type animals. Does LIN-39 control the same VD- and VC-specific terminal identity genes that become ectopically expressed in *unc-3* mutants?

To this end, we leveraged our endogenous *lin-39* reporter (*lin-39::mNG::3xFLAG::AID*) to assess expression in wild-type VD neurons at the mid-body region of the VNC, and found this to be the case ([Figure 7A](#fig7){ref-type="fig"}, [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). Next, we found that LIN-39 is required to induce expression of VD terminal identity genes (*ser-2, oig-1*) ([Figure 7B](#fig7){ref-type="fig"}). To gain further mechanistic insights, we then asked whether *lin-39* acts together with UNC-30, the known activator of GABAergic MN identity genes ([@bib19]; [@bib36]). Apart from confirming previous observations of UNC-30 controlling the VD-specific *oig-1* gene ([@bib14]; [@bib31]), we also found that *ser-2* ([Figure 7B](#fig7){ref-type="fig"}) and *flp-11* ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}, panel E) constitute novel UNC-30 targets in VD neurons. To test for synergistic effects, we focused on *ser-2* and *flp-11*, two VD-expressed terminal identity genes mildly affected in *lin-39* or *unc-30* single mutants. We generated *lin-39; unc-30* double mutants and observed stronger effects than either single mutant ([Figure 7B](#fig7){ref-type="fig"}, [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}, panel E). Such additive effects indicate that *lin-39* and *unc-30* act in parallel to activate VD terminal identity genes. Importantly, expression of other UNC-30 targets in GABAergic MNs, such as *flp-13* (DD-specific terminal identity marker) ([@bib14]; [@bib71]; [@bib87]) and genes expressed in both DD and VD neurons (*unc-25/GAD*, *unc-47/VGAT*), is unaffected in *lin-39* mutants ([Figure 7B](#fig7){ref-type="fig"}, [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}, panel F). Unlike UNC-30 that broadly controls multiple terminal features (NT identity and VD-specific terminal features) in VD neurons, we conclude that *lin-39* is selectively required for activation of VD-specific terminal identity genes ([Figure 7F](#fig7){ref-type="fig"}). To test for a maintenance role in VD neurons, we administered auxin at various post-developmental stages (L3, L4, day one adult) on animals carrying the *lin-39::mNG::3xFLAG::AID* allele. We found that LIN-39 is continuously required to maintain expression of the VD terminal identity gene *ser-2* ([Figure 7C](#fig7){ref-type="fig"}).

![LIN-39 is an activator of VD terminal identity genes.\
(**A**) Schematic summarizing *unc-30* and *lin-39* expression in VD and DD neurons populating the VNC. In addition, 4 VD and 2 DD neurons are located in ganglia flanking the VNC (not shown because they were excluded from our analysis). Raw data on *lin-39* expression described in [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}. (**B**) Quantification of two VD (*ser-2::gfp, oig-1::gfp*) and one DD (*flp-13::gfp*) markers in WT and *lin-39 (n1760)* animals at L4. Both VD markers were also tested in *unc-30 (e191)* mutants. Double *lin-39 (n1760); unc-30 (e191)* mutants showed a more severe reduction in expression of the VD marker *ser-2::gfp* compared to each single mutant. N \> 15. \*\*\*p\<0.001. N. S: not significant. (**C**) Auxin or ethanol (control) were administered at larval stage 3 (L3) on *lin-39::mNG::3xFLAG::AID; eft-3::TIR1* animals carrying the VD marker *ser-2::gfp.* Images were taken at the young adult stage (day 1.5). A significant decrease in the number of MNs expressing the VD marker was evident in the auxin-treated animals compared to EtOH-treated controls. Similar results were obtained when auxin administration occurred at L4 or day one adult animals. For comparison, quantification of marker expression is also provided in WT and *lin-39 (n1760)* animals. N \> 15. \*\*p\<0.01, \*\*\*p\<0.001. N. S: not significant. (**D**) Several terminal identity markers of cholinergic neurons (*acr-2, slo-2, unc-129, del-1*) are not ectopically expressed in *unc-30*-depleted GABAergic MNs. A strong loss-of-function allele *e191* for *unc-30* was used ([@bib8]; [@bib19]). Arrowheads point to MN cell bodies with *gfp* marker expression. Green fluorescence signal is shown in white for better contrast. (**E**) Quantification of data presented in panel D. N. S: not significant. (**F**) Schematic summarizing the function of LIN-39 and UNC-30 in GABAergic VD neurons. LIN-39 site is taken from [@bib82]. UNC-30 site is taken from [@bib87].](elife-50065-fig7){#fig7}

The above genetic analysis indicates that LIN-39 and UNC-30/PITX activate expression of VD-specific genes (left panel in [Figure 7F](#fig7){ref-type="fig"}). Similarly, LIN-39 and UNC-3 directly co-activate terminal identity genes in cholinergic MNs (left panel in [Figure 5D](#fig5){ref-type="fig"}). Since the absence of UNC-3 leads to ectopic activation of VD-specific genes ([Figure 5D](#fig5){ref-type="fig"}), we next considered the converse possibility: Does the absence of UNC-30/PITX lead to ectopic activation of cholinergic MN terminal identity genes in GABAergic VD neurons? However, this appears not to be the case as expression of 4 cholinergic MN markers (*acr-2, slo-1, unc-129, del-1*), normally co-activated by UNC-3 and LIN-39 ([Figure 5A--B](#fig5){ref-type="fig"}), is unaffected in *unc-30* mutants ([Figure 7D--F](#fig7){ref-type="fig"}).

Similar to its role in sex-shared VD neurons, does *lin-39* control expression of terminal identity genes in sex-specific VC neurons? We used the auxin-inducible *lin-39::mNG::3xFLAG::AID* allele to address this question because, unlike all other nerve cord MNs, the VC neurons do not survive in *lin-39 (n1760)* null animals ([@bib61]). We applied auxin at a late larval stage (L3-L4) to knock-down LIN-39 and observed that VC neurons do not die, providing an opportunity to test for putative effects on VC terminal identity gene expression. Indeed, we found a statistically significant reduction in the number of VC neurons expressing *srb-16* (compare auxin and ethanol in [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}, panel D).

Taken together, *lin-39* is required for expression of VD- and VC-specific terminal identity genes. In VD neurons, LIN-39 acts together with UNC-30/PITX to activate expression of VD-specific genes (left panel in [Figure 7F](#fig7){ref-type="fig"}). Collectively, these findings on VD and VC neurons together with observations on cholinergic MNs ([Figure 5D](#fig5){ref-type="fig"}) show that, in different MN subtypes, the mid-body Hox gene *lin-39* controls expression of distinct terminal identity genes, likely due to collaboration with distinct TFs (i.e., UNC-3 and MAB-5 in cholinergic MNs versus UNC-30 in VD neurons \[compare [Figure 5D](#fig5){ref-type="fig"} and [Figure 7F](#fig7){ref-type="fig"}\]).

LIN-39 acts through distinct *cis*-regulatory elements to control *oig-1* expression in VD and VD-like motor neurons {#s2-9}
--------------------------------------------------------------------------------------------------------------------

Does LIN-39 act directly or indirectly to activate VD and VC terminal identity genes? Analysis of available ChIP-Seq data (modENCODE project) indicates direct regulation of these genes by LIN-39 ([Figure 8A](#fig8){ref-type="fig"}, [Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}). However, the low resolution of ChIP-Seq data does not allow the identification of the exact DNA sequence recognized by LIN-39. Therefore, we interrogated the *cis*-regulatory region of two VD terminal identity genes *oig-1* and *ser-2* for the presence of the consensus LIN-39 binding site GATTGATG ([@bib7]) and found several copies located within the boundaries of the LIN-39 ChIP-Seq peaks in *oig-1* and *ser-2* ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). To test the functionality of these putative LIN-39 binding sites, we honed in on *oig-1* and performed a systematic *cis-*regulatory analysis in the context of transgenic reporter animals. A previous study identified a minimal 125 bp *cis*-regulatory element (contained within the LIN-39 peak boundaries) upstream of *oig-1* as sufficient to drive reporter gene expression in VD neurons ([@bib31]) ([Figure 8A](#fig8){ref-type="fig"}). We independently confirmed this observation, and further found that the 125 bp element contains a single LIN-39 site. Mutation of this site in the context of transgenic *oig-1* reporter animals (*oig-1 ^125bp\ LIN-39\ site\ MUT^::tagRFP*) leads to a significant reduction of tagRFP expression in VD neurons ([Figure 8A--B](#fig8){ref-type="fig"}), phenocoping the effect observed in *lin-39 (n1760)* null mutants ([Figure 7B](#fig7){ref-type="fig"}). We conclude that, in wild-type animals, LIN-39 acts directly, by recognizing its cognate site, to activate expression of the VD-specific gene *oig-1*. Interestingly, a functional binding site for UNC-30/PITX also exists in this 125 bp element ([@bib31]; [@bib87]), and is spaced 11 base pairs apart from the LIN-39 site ([Figure 7D](#fig7){ref-type="fig"}), indicating that LIN-39 and UNC-30 control *oig-1* by recognizing distinct and in close proximity *cis*-regulatory motifs. Moreover, available UNC-30 ChIP-Seq data further support this possibility as UNC-30 and LIN-39 ChIP-Seq peaks largely overlap at this 125 bp element ([Figure 8A](#fig8){ref-type="fig"}). Lastly, deletion of the region where LIN-39 and UNC-30 peaks overlap in the context of a 2.6 kb *oig-1* reporter (*oig-1 ^2.6kb\ LIN-39\ peak\ \#3\ DEL^*) abolish reporter expression in VD neurons ([Figure 8A--B](#fig8){ref-type="fig"}).

![LIN-39 acts through distinct *cis*-regulatory elements to activate *oig-1* expression in VD and VD-like neurons.\
(**A**) ChIP-Seq tracks are shown for UNC-30 (the top two) and LIN-39 (the bottom two) on VD gene oig-1 locus. The UNC-30 data were obtained from [@bib87]. The LIN-39 data come from the modENCODE project ([@bib7]). Four LIN-39 peaks are annotated with peak\#3 largely overlapping with UNC-30 peak. The results of *cis*-regulatory analysis in both WT and *unc-3* mutants are shown in the lower panel (aligned to the ChIP-seq tracks). Expression patterns of at least two transgenic lines were analyzed for each construct. '+\' indicates consistent and bright expression in ventral nerve cord (VNC) MNs (either VD or cholinergic). '+/−\' indicates consistent and bright expression in noticeable less number of VNC MNs. '−\' indicates no or extremely dim expression in VNC MNs. 'N.D.\': Not determined. In the schematic of the transgenes, a known UNC-30 site is shown as a blue box and a bioinformatically predicted LIN-39 site is represented as a black circle (filled circle indicates the presence of the site while unfilled one indicates deletion of the site). MUT indicates deletion of the LIN-39 site and DEL indicates deletion of the respective LIN-39 peak region. (**B**) Images (top part) and quantifications (bottom part) of selected constructs in the *cis*-regulatory analysis shown in (**A**). Animals carrying the *oig-1^125bp^::tagRFP* (left panel) with the LIN-39 site deleted show reduced tagRFP reporter expression in VD neurons; animals carrying the *oig-1^2.6kb\ LIN-39\ peak\ \#3\ DEL^* (middle panel) ectopically express the reporter in cholinergic MNs of *unc-3* mutants, but not in WT animals; animals carrying the *oig-1^2.6kb\ LIN-39\ peak\ \#4\ DEL^* (right panel) do not show ectopic reporter expression in *unc-3*-depleted MNs, but do show VD expression in both wild-type and *unc-3* mutants. N \> 12. \*\*\*p\<0.001. N. S: not significant.](elife-50065-fig8){#fig8}

We next asked whether LIN-39 acts through the same or distinct *cis*-regulatory elements to drive *oig-1* expression in VD versus VD-like neurons of *unc-3* mutants. While *oig-1* reporters in the context of a large (32.5 kb) genomic clone (fosmid) or a 2.6 kb intergenic region do show expression in both VD and VD-like neurons of *unc-3* mutants, reporter animals carrying 1 kb of *cis*-regulatory sequence (that contains the 125 bp element) immediately upstream of ATG showed expression only in VD neurons ([Figure 8A](#fig8){ref-type="fig"}). Conversely, a distal 1.6 kb element displayed expression in VD-like cells, but no expression in VD neurons of either WT or *unc-3* animals, suggesting the VD and VD-like elements are physically separated on the genome. Within the 1.6 kb element, there is a LIN-39 binding peak (peak \#4) based on available ChIP-Seq data on WT animals. Deletion of this peak in the context of a 2.6 kb *oig-1* reporter (*oig-1 ^2.6kb\ LIN-39\ peak\ \#4\ DEL^*) resulted in loss of expression in VD-like cells of *unc-3* mutants, whereas reporter expression was maintained in VD neurons ([Figure 8A--B](#fig8){ref-type="fig"}). This analysis strongly suggests that LIN-39 acts through distinct *cis*-regulatory elements to activate *oig-1* expression in VD versus VD-like cells.

The LIN-39-mediated transcriptional switch depends on UNC-3 and LIN-39 levels {#s2-10}
-----------------------------------------------------------------------------

How does the absence of UNC-3 lead to ectopic and *lin-39*-dependent activation of VD terminal identity genes in cholinergic MNs ([Figure 9D](#fig9){ref-type="fig"})? In principle, UNC-3 and LIN-39 could physically interact in order to co-activate expression of cholinergic MN terminal identity genes. In the absence of *unc-3*, this interaction would be disrupted and LIN-39 becomes available, in cholinergic MNs, to assume its VD function, that is to activate VD-specific terminal identity genes ([Figure 9D](#fig9){ref-type="fig"}). Although our co-immunoprecipitation (co-IP) experiments on UNC-3 and LIN-39 in a heterologous system (HEK cells) did not provide evidence for physical interaction ([Figure 9---figure supplement 1](#fig9s1){ref-type="fig"}), the heterologous context of this experiment still leaves open the possibility that, in cholinergic MNs in vivo, UNC-3 directly (or indirectly) recruits LIN-39 on terminal identity gene promoters. This scenario is supported by the observed decrease of LIN-39 binding on cholinergic MN gene loci in *unc-3* mutants ([Figure 5C](#fig5){ref-type="fig"}). Lastly, the gene dosage experiments presented below firmly suggest there is a close stoichiometric relationship between UNC-3 and LIN-39, reminiscent of LIM homeodomain TF stoichiometries described in vertebrate MNs ([@bib74]).

![Gene dosage experiments suggest that LIN-39 is the rate-limiting factor.\
(**A**) The endogenous expression levels of UNC-3 are higher than LIN-39. The DIC and mNG channels of two worms next to each other on the same slide with the genotype of *lin-39::mNG::3xFLAG::AID* (top, anterior right, ventral up) and *unc-3::mNG::3xFLAG::AID* (bottom, anterior left, ventral down) respectively are shown on the left. VNC regions indicated by dashed frame (**a, b**) are zoomed in at the middle panel with dashed circles around MN nuclei. The identities of these MNs are shown (e.g., VA8, VB9). The same cholinergic MNs have stronger expression levels of endogenous *unc-3::mNG* than *lin-39::mNG*. Quantification of the fluorescence intensities is shown on the right panel. For details on the quantification, see Materials and Materials and methods. N = 12. \*\*\*p\<0.001. (**B**) Quantification of the VD marker (*ser-2::gfp*) in *unc-3 (n3435), unc-3 (n3435); lin-39 (n1760)/+, unc-3 (n3435)/+, unc-3 (n3435); lin-39 (n1760), unc-3 (n3435)/+; lin-39 (n1760)/+,* and WT animals at L4. N \> 15. \*\*p\<0.01, \*\*\*p\<0.001. (**C**) Representative images of the VD marker (*ser-2::gfp*) expression on the left in L4 stage transgenic animals that either down-regulate *unc-3* in cholinergic MNs (*Punc-3 \>unc-3 RNAi*), over-express *lin-39* in cholinergic MNs (*Punc-3 \>lin-39 OE*), or over-express *unc-3* in VD neurons (VD prom \[*unc-47* prom\]*\>unc-3 OE*). Arrowheads point to MN cell bodies with *gfp* marker expression. Green fluorescence signal is shown in white for better contrast. Quantification is provided on the right. Two independent transgenic lines were used for *Punc-3 \>unc-3 RNAi* and *Punc-3 \>lin-39 OE.* N \> 13. \*\*\*p\<0.001. (**D**) Schematic summarizing the gene dosage experiments.](elife-50065-fig9){#fig9}

Because the decrease of LIN-39 binding is accompanied by ectopic activation of VD terminal identity genes in *unc-3*-depleted MNs, we hypothesized that LIN-39 is the rate-limiting factor present in limited amount in cholinergic MNs. That is, in the presence of UNC-3, LIN-39 activates cholinergic MN identity genes, but in its absence LIN-39 becomes available to activate alternative identity (e.g., VD) genes. Quantification of the endogenous expression levels of both proteins indeed showed lower levels of LIN-39 expression compared to UNC-3 ([Figure 9A](#fig9){ref-type="fig"}). Supporting the aforementioned hypothesis, we found a gene dosage relationship between *unc-3* and *lin-39*. Loss of one *unc-3* copy (*unc-3 (n3435)/+*) caused slight ectopic expression of VD genes (*ser-2* in [Figure 9B](#fig9){ref-type="fig"} and *flp-11* in [Figure 9---figure supplement 2](#fig9s2){ref-type="fig"}, panel A), but that ectopic expression is decreased by loss of one *lin-39* copy (*unc-3 (n3435)/+; lin-39 (n1760)/+*) ([Figure 9B](#fig9){ref-type="fig"}, [Figure 9---figure supplement 2](#fig9s2){ref-type="fig"}, panel A). Accordingly, loss of one *lin-39* copy in *unc-3* null animals (*unc-3 (n3435); lin-39 (n1760)/+*) also reduced, but did not eliminate, ectopic expression of VD genes ([Figure 9A](#fig9){ref-type="fig"}, [Figure 9---figure supplement 2](#fig9s2){ref-type="fig"}, panel A). Moreover, knock-down of *unc-3* with RNAi specifically in cholinergic MNs also led to ectopic expression of VD genes ([Figure 9C](#fig9){ref-type="fig"}, [Figure 9---figure supplement 2](#fig9s2){ref-type="fig"}, panels B-C), whereas ectopic expression of UNC-3 in VD neurons resulted in repression of VD gene expression, presumably by recruiting LIN-39 away from VD promoters ([Figure 9C](#fig9){ref-type="fig"}, [Figure 9---figure supplement 2](#fig9s2){ref-type="fig"}, panels B-C). Lastly, we asked whether LIN-39 is sufficient to induce expression of VD terminal identity genes in cholinergic MNs. Indeed, we found this to be the case ([Figure 9C](#fig9){ref-type="fig"}, [Figure 9---figure supplement 2](#fig9s2){ref-type="fig"}, panels D-E). In conclusion, we propose that the LIN-39-mediated transcriptional switch observed in *unc-3* mutants critically depends on UNC-3 and LIN-39 levels, with the latter being the rate-limiting factor ([Figure 9D](#fig9){ref-type="fig"}).

Ectopic expression of VD terminal identity genes in cholinergic motor neurons is associated with locomotion defects {#s2-11}
-------------------------------------------------------------------------------------------------------------------

The dual role of UNC-3 revealed by our molecular analysis ([Figure 2](#fig2){ref-type="fig"}) led us to posit that the severe locomotion defects observed in *unc-3* animals may represent a composite phenotype ([@bib8]; [@bib86]). In other words, these defects are not only due to loss of expression of cholinergic MN terminal identity determinants (e.g., *unc-17*/VAChT, *cha-1*/ChAT, *del-1*/Degenerin-like sodium channel, *acr-2*/acetylcholine receptor \[ortholog of CHRNE\]), but also due to the ectopic expression of VD and VC terminal features (e. g., *ser-2*/serotonin receptor \[ortholog of HTR1D\], *flp-11*/FRMR-like neuropeptide, *glr-5*/Glutamate receptor \[ortholog of GRID\], *srb-16*/GPCR) in *unc-3-*depleted MNs. To genetically separate these distinct molecular events, we generated *unc-3 (n3435); lin-39 (n1760)* double mutants, which do display loss of cholinergic MN terminal identity genes, but the ectopic expression of VD and VC terminal features is suppressed ([Figure 4F](#fig4){ref-type="fig"}). We predicted that if ectopic expression of VD and VC genes contributes to locomotion defects, then *unc-3 (n3435)* mutants would display more severe locomotion defects than *unc-3 (n3435); lin-39 (n1760)* double mutants. To test this, we performed high-resolution behavioral analysis of freely moving adult (day 1) *C. elegans* animals using automated multi-worm tracking technology ([@bib35]; [@bib86]). This analysis can quantitate multiple features related to *C. elegans* locomotion (*e.g.,* speed, crawling amplitude, curvature, pause, forward and backward locomotion) and, most importantly, each feature can be localized to a specific part of the nematode's body (e. g., head, mid-body, tail). Since *unc-3* and *lin-39* expression uniquely overlaps in mid-body nerve cord MNs that innervate mid-body muscles, we hypothesized that loss of *unc-3* and/or *lin-39* genes would have effects on mid-body posture and motion, and thereby focused our analysis on mid-body curvature features. Of the 49 mid-body features examined, 29 were significantly different in *unc-3* single mutants when compared to wild-type (N2 strain) animals (see [Supplementary file 3](#supp3){ref-type="supplementary-material"} for all 49 features). Intriguingly, 12 of these 29 features (41.37%) were significantly suppressed in *unc-3; lin-39* double mutants ([Figure 10A](#fig10){ref-type="fig"}, [Figure 10---figure supplement 1](#fig10s1){ref-type="fig"}, panel A, [Supplementary file 3](#supp3){ref-type="supplementary-material"}), suggesting that suppression of these behavioral defects could be attributed to suppression of the ectopically expressed VD and VC terminal identity genes in these double mutants. We found no evidence for suppression of the remaining 17 features in *unc-3; lin-39* double mutants, likely due to the fact that UNC-3 also controls other terminal identity genes, such as NT pathway genes ([Figure 9D](#fig9){ref-type="fig"}), independently of LIN-39.

![Ectopic expression of VD terminal identity genes in cholinergic motor neurons is associated with locomotion defects.\
(**A**) Examples of three mid-body locomotion features that are significantly affected in *unc-3 (n3435)* animals, but markedly improved in *unc-3 (n3435); lin-39 (n1760)* double mutant animals. Each black dot represents a single adult animal. The unit for the first two graphs is 1/microns. The unit for the graph on the right is 1/(microns\*seconds). N = 12. Additional mid-body features affected in *unc-3 (n3435)* animals, but improved in *unc-3 (n3435); lin-39 (n1760)* mutants are provided in [Figure 10---figure supplement 1](#fig10s1){ref-type="fig"} and [Supplementary file 3](#supp3){ref-type="supplementary-material"}. \*p\<0.01, \*\*p\<0.001, \*\*\*p\<0.0001. (**B**) Examples of three mid-body locomotion features affected in *unc-3 (n3435)* mutants and animals over-expressing *lin-39* in cholinergic MNs. Each black dot represents a single adult animal. The unit for the Y axis is 1/(microns\*seconds). N = 12. Additional mid-body features affected in *unc-3 (n3435)* and *lin-39* over-expressing animals are provided in [Figure 10---figure supplement 1](#fig10s1){ref-type="fig"} and [Supplementary file 3](#supp3){ref-type="supplementary-material"}. \*p\<0.01, \*\*p\<0.001, \*\*\*p\<0.0001. (**C**) Conceptual model summarizing the findings of this paper. Gray font: not expressed gene. Black font: expressed gene. Gray arrow: inactive genetic interaction. Black arrow: active genetic interaction.](elife-50065-fig10){#fig10}

Next, we asked whether ectopic expression of VD terminal identity genes in otherwise wild-type animals can lead to locomotion defects. To test this, we took advantage of our transgenic animals that selectively over-express LIN-39 in cholinergic MNs (*Pcho-1 \>LIN-39, Punc-3 \>LIN-39*) ([Figure 9C](#fig9){ref-type="fig"}, [Figure 10---figure supplement 1](#fig10s1){ref-type="fig"}, panel D). First, we confirmed that in these animals expression of cholinergic MN terminal identity genes is unaffected ([Figure 10---figure supplement 1](#fig10s1){ref-type="fig"}, panel D). Second, we found that LIN-39 overexpression led to ectopic activation of VD, but not VC, terminal identity genes in cholinergic MNs ([Figure 10---figure supplement 1](#fig10s1){ref-type="fig"}, panel D), providing an opportunity to specifically assess the consequences of ectopic VD gene expression on animal locomotion. We found that 9 of the 29 (31.03%) mid-body features affected in *unc-3 (n3435)* animals were also altered in animals over-expressing *lin-39* in cholinergic MNs ([Figure 10B](#fig10){ref-type="fig"}, [Figure 10---figure supplement 1](#fig10s1){ref-type="fig"}, panels B-C, [Supplementary file 3](#supp3){ref-type="supplementary-material"}).

In conclusion, our behavioral analysis is in agreement with our molecular findings. At the molecular level, we found that *lin-39*/Hox is necessary for the ectopic expression of VD terminal identity genes in *unc-3* mutants. At the behavioral level, this *lin-39*-dependent, ectopic expression of terminal identity genes is accompanied by locomotion defects.

Discussion {#s3}
==========

During development, individual neuron types must select their unique terminal identity features, such as expression of NT receptors, ion channels and neuropeptides. Continuous expression of these features - from development through adulthood - is essential for safeguarding neuronal terminal identity, and thereby ensuring neuronal function ([@bib17]; [@bib28]; [@bib29]). Here, we provide critical insights into the mechanisms underlying selection and maintenance of neuron type-specific terminal identity features by using the well-defined MN populations of the *C. elegans* nerve cord as a model. First, we report that, in cholinergic MNs, the terminal selector-type TF UNC-3 has a dual role; UNC-3 is not only required to promote cholinergic MN identity features ([@bib42]), but also to prevent expression of multiple terminal features normally reserved for three other ventral cord neuron types (VD, VC, CA). Second, we provide evidence that cholinergic MNs can secure their terminal identity throughout life by continuously relying on UNC-3's dual function. Third, we propose an unusual mechanism underlying this dual function, as we find UNC-3 necessary to prevent a switch in the transcriptional targets of the mid-body Hox protein LIN-39 (Scr/Dfd/Hox4-5) ([Figure 9D](#fig9){ref-type="fig"}). Lastly, our findings shed light upon the poorly explored, post-embryonic role of Hox proteins in the nervous system by uncovering that LIN-39 is continuously required to maintain expression of multiple terminal identity genes in MNs.

UNC-3 determines the function of the rate-limiting factor LIN-39/Hox in cholinergic motor neurons {#s3-1}
-------------------------------------------------------------------------------------------------

Numerous cases of neuron type-specific TFs with a dual role have been previously described in both vertebrate and invertebrate models systems ([@bib9]; [@bib13]; [@bib37]; [@bib47]; [@bib49]; [@bib52]; [@bib54]; [@bib65]). Although the underlying mechanisms often remain unclear, recent studies proposed two modes of action. First, such TFs can act directly to activate 'desired' terminal identity features and repress (also directly) alternative identity features ([@bib46]; [@bib85]). Second, neuron type-specific TFs can act indirectly by controlling intermediary factors. For example, in the mouse spinal cord, a complex of three TFs (Isl1, Lhx3, NLI) specifies MN identity by recognizing specific DNA elements in the *cis*-regulatory region of MN-specific genes and the homeodomain TF Hb9, and activates their expression. Hb9 functions as a transcriptional repressor of alternative (V2a interneuron) identity genes, thereby consolidating MN identity ([@bib45]; [@bib74]; [@bib78]). An analogous mechanism operates in V2a interneurons and involves Chx10, a homeodomain protein that represses alternative neuronal identity programs ([@bib16]; [@bib45]). Hence, mouse mutants for *Hb9* or *Chx10* result in ectopic expression of alternative identity genes ([@bib3]; [@bib16]; [@bib77]). Several TFs (*unc-4*/Uncx, *mab-9*/Tbx20, *unc-55*/COUP, *bnc-1*/BNC) with repressor activity are known to control aspects of cholinergic MN development in *C. elegans* ([@bib39]; [@bib57]; [@bib59]; [@bib81]; [@bib84]). However, their genetic removal did not result in ectopic expression of alternative (VD, VC) identity features in cholinergic MNs (data not shown). Although we cannot exclude the involvement of yet-to-be identified transcriptional repressors acting downstream of UNC-3, our genetic and biochemical analyses led us to propose the following mechanism underlying UNC-3's dual role.

In cholinergic MNs, *unc-3* and *lin-39* are co-expressed, albeit the latter in lower levels ([Figure 9A](#fig9){ref-type="fig"}), suggesting that LIN-39/Hox is a rate-limiting factor whose function is determined by UNC-3. In wild-type animals, UNC-3 and LIN-39 occupy *cis*-regulatory elements of cholinergic MN terminal identity genes, resulting in their activation ([Figure 5C](#fig5){ref-type="fig"}) ([@bib42]). In the absence of UNC-3, LIN-39 is released from these elements and becomes available to activate alternative identity genes, such as VD-specific terminal identity genes. Several lines of evidence support this conclusion. First, ChIP-seq data show that LIN-39 binding is decreased in cholinergic MN gene loci in *unc-3* mutants ([Figure 5C](#fig5){ref-type="fig"}). Second, our gene dosage experiments show that either lowering *unc-3* levels or increasing *lin-39* levels in cholinergic MNs results in ectopic activation of VD identity genes ([Figure 9B--C](#fig9){ref-type="fig"}). Lastly, we performed an extensive *cis*-regulatory analysis of one VD-specific gene (*oig-1*) and identified the element through which LIN-39 acts to induce *oig-1* expression in VD-like cells of *unc-3* mutants ([Figure 8](#fig8){ref-type="fig"}). Together, these data suggest that the role of UNC-3 in cholinergic MNs is not simply to activate gene expression with LIN-39, but also to 'recruit' LIN-39 away from promoters of alternative identity genes, thereby antagonizing its ability to activate those genes. Supporting this scenario, ectopic UNC-3 expression in VD neurons results in decreased expression of VD-specific genes ([Figure 9C](#fig9){ref-type="fig"}). Given that the mouse ortholog of *unc-3*, Ebf2, is co-expressed with Hox genes in cholinergic MNs of the spinal cord ([@bib12]; [@bib43]), the molecular mechanism described here may be conserved across species. Interestingly, a seminal study recently described a conceptually similar mechanism in the mouse retina, where CRX recruits MEF2D to retina-specific enhancers, resulting in selective activation of photoreceptor genes ([@bib2]).

Insights into how neurons maintain their terminal identity features throughout life {#s3-2}
-----------------------------------------------------------------------------------

Is there a need for mechanisms that continuously prevent expression of alternative identity features in a post-mitotic neuron? Or, do such mechanisms become superfluous once neurons have restricted their developmental potential by committing to a specific terminal identity? This fundamental question is poorly explored, in part due to the fact that most neuron type-specific TFs have been studied during embryonic stages. For example, it is not known whether CRX is continuously required to activate retina-specific enhancers and simultaneously prevent expression of alternative identity genes ([@bib2]). Our temporally controlled protein depletion experiments uncovered a continuous requirement for the dual role of UNC-3. Post-embryonic depletion of UNC-3 not only results in failure to maintain cholinergic MN terminal features ([@bib42]), but is also accompanied by ectopic expression of alternative identity features (e.g., VD, VC). These findings reveal a simple and economical mechanism that can enable individual neuron types to select and maintain their distinct terminal identity features. That is, the same TF is continuously required - from development throughout life - to not only activate neuron type-specific identity genes, but also prevent expression of alternative identity features.

Maintenance of terminal identity features: A new function of hox proteins in the nervous system {#s3-3}
-----------------------------------------------------------------------------------------------

Across model systems, a large body of work on motor neurons and other neuron types has established that, during early development, Hox proteins are required for neuronal diversity, cell survival, axonal path finding and circuit assembly ([@bib5]; [@bib11]; [@bib22]; [@bib21]; [@bib38]; [@bib50]; [@bib51]; [@bib53]; [@bib58]). However, the function and downstream targets of Hox proteins during post-embryonic stages are largely unknown. Our contributions towards this knowledge gap are twofold. First, we found that the mid-body Hox protein LIN-39 is continuously required, from development through adulthood, to control expression of MN terminal identity genes, thereby revealing a novel role for Hox proteins in maintaining neuronal identity. Second, we uncovered multiple terminal identity genes as downstream targets of LIN-39 in different MN subtypes (cholinergic MNs: *acr-2, dbl-1, unc-77, slo-2;* VD neurons: *oig-1, ser-2, flp-11;* VC neurons: *srb-16).* Since continuous expression of these genes is essential for MN function, these findings may provide a molecular explanation for the uncoordinated locomotion defects observed in *lin-39* mutants ([Figure 10---figure supplement 1](#fig10s1){ref-type="fig"}). Given the maintained expression of Hox genes in the adult nervous system of flies, mice and humans ([@bib5]; [@bib76]; [@bib32]), our findings may be broadly transferable.

Impact on the concept of terminal selector genes {#s3-4}
------------------------------------------------

TFs able to broadly activate many distinct terminal identity features of a specific neuron type (e.g., NT biosynthesis components, NT receptors, ion channels, neuropeptides) have been termed 'terminal selectors' ([@bib27]). Several dozens of terminal selectors have been described thus far in multiple model systems including worms, flies and mice ([@bib28]; [@bib29]; [@bib30]). However, it is unclear whether terminal selectors are also required to prevent expression of alternative identity features. Our findings suggest this to be the case by revealing a dual role for UNC-3, the terminal selector of cholinergic MN identity in *C. elegans*. In the future, it will be interesting to see whether other terminal selectors also exert a dual role in order to safeguard neuronal terminal identity. Supporting this possibility, Pet-1, the terminal selector of mouse serotonergic neurons has been recently shown to repress several terminal identity genes ([@bib85]).

Limitations and lessons learned about the control of neuronal terminal identity {#s3-5}
-------------------------------------------------------------------------------

The examination of multiple MN terminal identity markers at single-cell resolution enabled us to make an interesting observation. Although all *unc-3*-depleted nerve cord MNs uniformly lose their cholinergic identity, one subpopulation acquires VD terminal features ('VD-like' neurons) and another subpopulation acquires VC terminal features ('VC-like' neurons). This intriguing observation may be analogous to findings described in the mammalian neocortex, where genetic removal of the TF *Satb2* leads to loss of pyramidal neuron identity (UL1 subtype), and concomitant gain of molecular features specific to two other pyramidal neuron subtypes (DL, UL2) ([@bib9]). Together, the cases of UNC-3 and Satb2 support the notion that neuron type-specific TFs often suppress features of functionally related neuronal subtypes ([@bib4]).

Although our study employs an extensive repertoire of terminal identity markers for distinct MN subtypes, the extent of alternative identity features (e.g., VD, VC) being ectopically expressed in *unc-3*-depleted MNs remains unknown. Future unbiased transcriptional profiling of *unc-3-*depleted MNs could help address this issue. In addition, the strong axonal defects in MNs of *unc-3* mutants preclude any further attempts to assess whether the observed VD-like and VC-like cells, as defined by molecular markers, also acquire morphological features of VD and VC neurons, respectively ([@bib62]). However, the VD-like neurons of *unc-3* mutants do not acquire GABAergic identity like wild-type VD neurons ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}, panel A), arguing against a complete cell fate transformation.

Evolutionary implications of this study {#s3-6}
---------------------------------------

Our findings highlight the employment of economical solutions to evolve novel cell types in the nervous system. The same Hox protein (LIN-39) collaborates with distinct terminal selectors in different MNs, and this collaboration determines the specificity of LIN-39/Hox function. In GABAergic (VD) neurons, LIN-39 works together with UNC-30/PITX to control expression of VD terminal identity genes, whereas in cholinergic MNs LIN-39 synergizes with UNC-3 to control cholinergic MN identity genes ([Figure 7F](#fig7){ref-type="fig"}, [9D](#fig9){ref-type="fig"}). We speculate that the *unc-3* mutant 'state' may constitute the 'ground state'. That is, the 'VD-like' neurons, for example, in *unc-3* mutants that express LIN-39 may represent an ancient cell type that was altered to become a new cell type through the recruitment of distinct terminal selectors (conceptual model in [Figure 10C](#fig10){ref-type="fig"}). Hence, the amount of genetic information required for evolution of new cell types is kept to minimum. The recruitment of UNC-30/PITX enabled 'VD-like' cells to fully adopt GABAergic VD neuron terminal identity, as evident by the ability of UNC-30/PITX to control expression of GABA synthesis proteins ([@bib19]; [@bib36]) ([Figure 7F](#fig7){ref-type="fig"}). Similarly, recruitment of UNC-3 enabled 'VD-like' cells to become cholinergic MNs. In this 'new' cholinergic cell type, UNC-3 exerts a dual role: it antagonizes the ability of LIN-39 to activate VD-specific genes, and also synergizes with LIN-39 to co-activate cholinergic MN terminal identity genes ([Figure 9D](#fig9){ref-type="fig"}). We hope the strategy described here of a terminal selector preventing a Hox transcriptional switch may provide a conceptual framework for future studies on terminal identity and evolution of neuronal cell types.

Materials and methods {#s4}
=====================

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                                          Designation                                          Source or reference                                       Identifiers                                                                   Additional\
  (species) or resource                                                                                                                                                                                                                               information
  ------------------------------------------------------ ---------------------------------------------------- --------------------------------------------------------- ----------------------------------------------------------------------------- --------------------------------------------------------------
  Gene (*Caenorhabditis elegans*)                        *unc-3*                                              Wormbase                                                  WBGene00006743                                                                

  Gene (*Caenorhabditis elegans*)                        *unc-30*                                             Wormbase                                                  WBGene00006766                                                                

  Gene (*Caenorhabditis elegans*)                        *lin-39*                                             Wormbase                                                  WBGene00003024                                                                

  Gene (*Caenorhabditis elegans*)                        *mab-5*                                              Wormbase                                                  WBGene00003102                                                                

  Strain, strain background (*Caenorhabditis elegans*)   *unc-3 (n3435)*                                      Bob Horvitz\                                              MT10785                                                                       Null Allele: deletion
                                                                                                              (MIT, Cambridge MA)                                                                                                                     

  Strain, strain background (*Caenorhabditis elegans*)   *unc-30 (e191)*                                      Caenorhabditis Genetics Center                            CB845                                                                         Allele: substitution

  Strain, strain background (*Caenorhabditis elegans*)   *lin-39(n1760)/dpy-17(e164) unc-32(e189) III.*       Caenorhabditis Genetics Center                            MT4009                                                                        Null Allele: substitution

  Strain, strain background (*Caenorhabditis elegans*)   *mab-5 (n1239) III*; *him-5 (e1490) V*               Caenorhabditis Genetics Center                            CB3531                                                                        Allele: substitution

  Strain, strain background (*Caenorhabditis elegans*)   *him-8 (e1489) IV*                                   Caenorhabditis Genetics Center                            CB1489                                                                        Allele: substitution

  Strain, strain background (*Caenorhabditis elegans*)   *ieSi57 II; unc-3* (*ot837 \[unc-3::mNG::AID\]*)     Caenorhabditis Genetics Center                            OH13988                                                                       CRISPR-generated allele

  Strain, strain background (*Caenorhabditis elegans*)   *lin-39 (kas9* \[*lin-39::mNG::AID\]*)               This paper                                                KRA110                                                                        See Materials and methods, Section Targeted genome editing

  Strain, strain background (*Caenorhabditis elegans*)   *ieSi57 \[eft-3prom::tir1\]*                         Caenorhabditis Genetics Center                            CA1200                                                                        Genotype: *ieSi57 II*;\
                                                                                                                                                                                                                                                      *unc-119(ed3) III*.

  Strain, strain background (*Caenorhabditis elegans*)   *ser-2::gfp*                                         Caenorhabditis Genetics Center                            OH2246                                                                        Genotype: *otIs107 I*

  Strain, strain background (*Caenorhabditis elegans*)   *oig-1::gfp*                                         Caenorhabditis Genetics Center                            OH3955                                                                        Genotype: *pha-1*(*e2123*) *III; otEx193*

  Strain, strain background (*Caenorhabditis elegans*)   *ida-1::gfp*                                         Caenorhabditis Genetics Center                            BL5717                                                                        Genotype: *inIs179 II; him-8(e1489) IV*

  Strain, strain background (*Caenorhabditis elegans*)   *glr-5::gfp*                                         Aixa Alfonso (University of Illinois, Chicago IL)         AL270                                                                         Genotype: *icIs270 X*

  Strain, strain background (*Caenorhabditis elegans*)   *srb-16::gfp*                                        Caenorhabditis Genetics Center                            BC14820                                                                       Genotype:*dpy-5(e907) I; sEx14820*

  Strain, strain background (*Caenorhabditis elegans*)   *flp-11::gfp*                                        Caenorhabditis Genetics Center                            NY2040                                                                        Genotype: *ynIs40 V*

  Strain, strain background (*Caenorhabditis elegans*)   *twk-46::gfp*                                        Caenorhabditis Genetics Center                            BC13337                                                                       Genotype: *dpy-5(e907) I; sIs12928 V*

  Strain, strain background (*Caenorhabditis elegans*)   *ilys-4::tagrfp*                                     This paper                                                KRA22                                                                         Genotype: *pha-1(e2123) III; kasEx22*

  Strain, strain background (*Caenorhabditis elegans*)   *flp-13::gfp*                                        Caenorhabditis Genetics Center                            NY2037                                                                        Genotype: *ynIs37 III*

  Strain, strain background (*Caenorhabditis elegans*)   *lin-11::mCherry*                                    Oliver Hobert (Columbia University, New York NY)          OH11954                                                                       Genotype: *lin-11::mCherry + myo-2::GFP V*

  Strain, strain background (*Caenorhabditis*\           *klp-4::gfp*                                         Caenorhabditis Genetics Center                            BC11799                                                                       Genotype: *dpy-5(e907) I; sEx11799*
  *elegans*)                                                                                                                                                                                                                                          

  Strain, strain background (*Caenorhabditis elegans*)   *alr-1::egfp*                                        Caenorhabditis Genetics Center                            OP200                                                                         Genotype: *unc-119(ed3) III; wgIs200 X*

  Strain, strain background (*Caenorhabditis elegans*)   *irx-1::egfp*                                        Caenorhabditis Genetics Center                            OP536                                                                         Genotype: *unc-119*(*tm4063*) *III; wgIs536 I*

  Strain, strain background (*Caenorhabditis elegans*)   *del-1::gfp*                                         Caenorhabditis Genetics Center                            NC138                                                                         

  Strain, strain background (*Caenorhabditis elegans*)   *acr-2::gfp*                                         Caenorhabditis Genetics Center                            CZ631                                                                         Genotype: *juIs14 IV*

  Strain, strain background (*Caenorhabditis elegans*)   *unc-129::gfp*                                       Caenorhabditis Genetics Center                            *evIs82b*                                                                     Genotype: *evIs82b IV*

  Strain, strain background (*Caenorhabditis elegans*)   *dbl-1::gfp*                                         Caenorhabditis Genetics Center                            BW1935                                                                        Genotype: *unc-119(ed3) III; ctIs43 him-5(e1490) V*

  Strain, strain background (*Caenorhabditis elegans*)   *nca-1::gfp*                                         Caenorhabditis Genetics Center                            BC15028                                                                       Genotype: *dpy-5(e907) I; sEx15028*

  Strain, strain background (*Caenorhabditis elegans*)   *slo-2::gfp*                                         Caenorhabditis Genetics Center                            BC10749                                                                       Genotype: *dpy-5(e907) I; sEx10749*

  Strain, strain background (*Caenorhabditis elegans*)   *ttr-39::mCherry*                                    Caenorhabditis Genetics Center                            CZ8332                                                                        Genotype: *juIs223 IV*

  Strain, strain background (*Caenorhabditis elegans*)   *cho-1::rfp*                                         Caenorhabditis Genetics Center                            OH13646                                                                       Genotype: *pha-1(e2123) III; him-5(e1490) otIs544 V*

  Strain, strain background (*Caenorhabditis elegans*)   *unc-17::gfp*                                        Caenorhabditis Genetics Center                            LX929                                                                         Genotype: *vsIs48 X*

  Strain, strain background (*Caenorhabditis elegans*)   *unc-25::gfp*                                        Caenorhabditis Genetics Center                            CZ13799                                                                       Genotype: *juIs76 II*

  Strain, strain background (*Caenorhabditis elegans*)   *unc-47::mChOpti*                                    Caenorhabditis Genetics Center                            OH13105                                                                       Genotype: *him-5(e1490) otIs564 V*

  Strain, strain background (*Caenorhabditis elegans*)   *unc-30::gfp*                                        Caenorhabditis Genetics Center                            OP395                                                                         Genotype: *unc-119(tm4063) III*;\
                                                                                                                                                                                                                                                      *wgIs395*

  Strain, strain background (*Caenorhabditis elegans*)   *ser-2::rfp*                                         Mark Alkema (University of Massachusetts, Worcester MA)   AL270                                                                         Genotype: *zfIs8 IV*

  Strain, strain background (*Caenorhabditis elegans*)   *oig-1(fosmid)::GFP*                                 Caenorhabditis Genetics Center                            OH11809                                                                       Genotype: *otIs450*

  Strain, strain background (*Caenorhabditis elegans*)   *lin-39::gfp*                                        Caenorhabditis Genetics Center                            OP18                                                                          Genotype: *unc-119(ed3) III; wgIs18*

  Genetic reagent (*Caenorhabditis elegans*)             *Poig-1_1 kb::gfp*                                   Oliver Hobert (Columbia University, New York NY)          otEx5993\                                                                     
                                                                                                                                                                        otEx5994\                                                                     
                                                                                                                                                                        otEx5995                                                                      

  Genetic reagent (*Caenorhabditis elegans*)             *Poig-1_1.6 kb::gfp*                                 This paper                                                kasEx147\                                                                     See Materials and methods
                                                                                                                                                                        kasEx148                                                                      

  Genetic reagent (*Caenorhabditis elegans*)             *Poig-1_2.6 kb_LIN-39*\                              This paper                                                kasEx149\                                                                     See Materials and methods
                                                         *site \#3 DEL::gfp*                                                                                            kasEx150                                                                      

  Genetic reagent (*Caenorhabditis elegans*)             *Poig-1_2.6 kb_LIN-39 site \#4 DEL::gfp*             This paper                                                kasEx151\                                                                     See Materials and methods
                                                                                                                                                                        kasEx152                                                                      

  Genetic reagent (*Caenorhabditis elegans*)             *Poig-1_125 bp\_::tagrfp*                            This paper                                                kasEx80\                                                                      See Materials and methods
                                                                                                                                                                        kasEx81\                                                                      
                                                                                                                                                                        kasEx82                                                                       

  Genetic reagent (*Caenorhabditis elegans*)             *Poig-1\_ LIN-39 site mut 125 bp\_::tagrfp*          This paper                                                kasEx91\                                                                      See Materials and methods
                                                                                                                                                                        kasEx92\                                                                      
                                                                                                                                                                        kasEx93                                                                       

  Genetic reagent (*Caenorhabditis elegans*)             *Punc-3_558bp \> lin-39 RNAi + myo-2::gfp*           This paper                                                kasEx68\                                                                      See Materials and methods
                                                                                                                                                                        kasEx69\                                                                      
                                                                                                                                                                        kasEx70\                                                                      
                                                                                                                                                                        kasEx71\                                                                      
                                                                                                                                                                        kasEx72                                                                       

  Genetic reagent (*Caenorhabditis elegans*)             *Punc-3_558bp \> unc-3 RNAi + myo-2::gfp*            This paper                                                kasEx73\                                                                      See Materials and methods
                                                                                                                                                                        kasEx74\                                                                      
                                                                                                                                                                        kasEx78\                                                                      
                                                                                                                                                                        kasEx79                                                                       

  Genetic reagent (*Caenorhabditis elegans*)             *Punc-3_558bp \> lin-39 cDNA OE + myo-2::gfp*        This paper                                                kasEx35\                                                                      See Materials and methods
                                                                                                                                                                        kasEx36\                                                                      
                                                                                                                                                                        kasEx37\                                                                      
                                                                                                                                                                        kasEx76\                                                                      
                                                                                                                                                                        kasEx77                                                                       

  Genetic reagent (*Caenorhabditis elegans*)             *Punc-47 \> unc-3 cDNA + myo-2::gfp*                 This paper                                                kasEx75                                                                       See Materials and methods

  Genetic reagent (*Caenorhabditis elegans*)             *Pcho-1_280bp \> lin-39 cDNA OE + myo-2::gfp*        This paper                                                kasEx38\                                                                      See Materials and methods
                                                                                                                                                                        kasEx39\                                                                      
                                                                                                                                                                        kasEx41                                                                       

  Genetic reagent (*Caenorhabditis elegans*)             *lin-39 fosmid WRM0616aE11 + myo-2::gfp*             This paper                                                kasEx33\                                                                      See Materials and methods
                                                                                                                                                                        kasEx34                                                                       

  Antibody                                               anti-Myc (Rabbit polyclonal)                         Abcam                                                     \#ab9106; RRID:[AB_307014](https://scicrunch.org/resolver/AB_307014)          1:1000 dilution

  Antibody                                               anti-Flag (Mouse monoclonal)                         Sigma                                                     \#F3165; RRID:[AB_259529](https://scicrunch.org/resolver/AB_259529)           1:1000 dilution

  Antibody                                               anti-Flag (Rabbit polyclonal)                        Sigma,                                                    \#SAB4301135; RRID: [AB_2811010](https://scicrunch.org/resolver/AB_2811010)   1:1000 dilution

  Antibody                                               Clean-Blot IP Detection Reagent (Mouse monoclonal)   Thermo Fisher                                             \#21230; RRID: [AB_2576514](https://scicrunch.org/resolver/AB_2576514)        See Materials and methods

  Antibody                                               Flag antibody coated beads (Mouse monoclonal)        Sigma,                                                    \#A2220; RRID:[AB_10063035](https://scicrunch.org/resolver/AB_10063035)       See Materials and methods

  Antibody                                               anti-FLAG M2 magnetic beads (Mouse monoclonal)       Sigma-Aldric                                              M8823; RRID: [AB_2637089](https://scicrunch.org/resolver/AB_2637089)          See Materials and methods

  Recombinant DNA reagent                                pcDNA 3.1(+)- C-Flag (Plasmid)                       Genscript                                                 pcDNA 3.1(+)                                                                  C-terminus Flag-tagged UNC-3

  Recombinant DNA reagent                                pcDNA 3.1(+)-N-Myc (Plasmid)                         Genscript                                                 pcDNA 3.1(+)                                                                  N-terminus Myc-tagged LIN-39

  Recombinant DNA reagent                                Fosmid clone WRM0616aE11                             Source BioScience                                         WRM0616aE11                                                                   *lin-39::GFP*\
                                                                                                                                                                                                                                                      fosmid clone

  Commercial assay or kit                                Gibson Assembly Cloning Kit                          NEB                                                       \#5510S                                                                       

  Commercial assay or kit                                QIAquick PCR Purification Kit                        QIAGEN                                                    \#28104                                                                       

  Commercial assay or kit                                Ampure XP beads                                      Beckman Coulter Life Sciences                             A63881                                                                        

  Commercial assay or kit                                TOPO XL-2 Complete PCR Cloning Kit                   Thermo Fisher                                             K8050                                                                         

  Chemical compound, drug                                Auxin (indole-3-acetic acid)                         Alfa Aesar                                                \#10196875                                                                    

  Software, algorithm                                    ZEN                                                  ZEISS                                                     Version 2.3.69.1000,\                                                         RRID:[SCR_013672](https://scicrunch.org/resolver/SCR_013672)
                                                                                                                                                                        Blue edition                                                                  

  Software, algorithm                                    Image J                                              Image J                                                   Version 1.52i                                                                 RRID:[SCR_003070](https://scicrunch.org/resolver/SCR_003070)

  Software, algorithm                                    RStudio                                              RStudio                                                   Version 1.2.5001                                                              

  Software, algorithm                                    Adobe Photoshop CS6                                  Adobe                                                     Version 13.0 × 64                                                             

  Software, algorithm                                    Adobe Illustrator CS6                                Adobe                                                     Version 16.0.0 × 64                                                           
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*C. elegans* strains {#s4-1}
--------------------

Worms were grown at 15 °C, 20 °C or 25 °C on nematode growth media (NGM) plates seeded with bacteria (*E.coli* OP50) as food source ([@bib8]).

Forward genetic screen {#s4-2}
----------------------

EMS mutagenesis was performed on *unc-3 (n3435); ynIs40 \[flp-11::GFP\]* animals using standard procedures ([@bib44]). Mutagenized L4 animals were visually screened at a dissecting fluorescence microscope for changes in *flp-11::GFP* expression in VNC MNs. One mutant (*kas1*) was retrieved.

Generation of transgenic reporter animals {#s4-3}
-----------------------------------------

Reporter gene fusions for *cis*-regulatory analysis of terminal identity genes were made using either PCR fusion ([@bib26]) or Gibson Assembly Cloning Kit (NEB \#5510S). Targeted DNA fragments were fused (ligated) to *tagrfp* coding sequence, which was followed by *unc-54 3' UTR.* The TOPO XL PCR cloning kit was used to introduce the PCR fusion fragments into the pCR-XL-TOPO vector (Invitrogen). Mutations on LIN-39 motifs were introduced via mutagenesis PCR. The product DNA fragments were either injected into young adult *pha-1(e2123)* hermaphrodites at 50 ng/µl using *pha-1* (pBX plasmid) as co-injection marker (50 ng/µl) and further selected for survival, or injected into young adult N2 hermaphrodites at 50 ng/µl (plus 50 ng/µl pBX plasmid) using *myo-2::gfp* as co-injection marker (3 ng/µl) and further selected for GFP signal.

The fosmid clone WRM0616aE11 (genomic region: III:7519128..7554793) (Source BioScience) that contains the entire *lin-39* locus was linearized by restriction enzyme digestion, mixed with sonicated bacterial genomic DNA (12 ng/µl) and injected into young adult N2 hermaphrodites at 15 ng/µl using *myo-2::gfp* as co-injection marker (3 ng/µl).

Generation of transgenic animals for RNAi or over-expression {#s4-4}
------------------------------------------------------------

The cDNA (for over-expression) or the exon-rich genomic region (for RNAi) of *unc-3* and *lin-39* were amplified by PCR and then ligated to cholinergic (*cho-1, unc-3*) or GABAergic (*unc-47*) MN promoters using Gibson Assembly Cloning Kit (NEB \#5510S). For *unc-3* RNAi, we targeted exons 2--5 with the following primers: FRW: GTCTGTAAAAGATGAGAACCAGCGG, RVS: CTGTCAATAATAACTGGATCGCTGG. For *lin-39* RNAi, we targeted exons 3--5 with the following primers: FRW: gtggtcaaactccgaacttaaagtg, RVS: gaaggggcgagaaatgtgtgataac. For over-expression constructs, DNA products were purified using a PCR purification protocol (QIAGEN), and then injected into young adult WT hermaphrodites at 50 ng/µl together with 50 ng/µl pBS plasmid (filler DNA) and 3 ng/µl of *myo-2::gfp* (co-injection marker). For RNAi constructs, complementary sense and anti-sense exon-rich genomic regions of *unc-3* and *lin-39* were PCR purified and injected into young adult WT or *unc-3 (n3435)* hermaphrodites each at 100 ng/µl with *myo-2::gfp* as co-injection marker (3 ng/µl) following previously established procedures ([@bib20]).

Targeted genome engineering {#s4-5}
---------------------------

To generated the *lin-39 (kas9 \[lin-39::mNG::AID\])* allele, CRISPR/Cas9 genome editing was employed to introduce the *mNG::3xFLAG::AID* cassette into the *lin-39* gene locus before the stop codon. Micro-injection, selection and strain establishment were performed as previously described ([@bib18]).

Temporally-controlled protein degradation {#s4-6}
-----------------------------------------

In the presence of TIR1, AID-tagged proteins are conditionally degraded when exposed to auxin in the presence of TIR1 ([@bib88]). Animals carrying auxin-inducible alleles of *lin-39 (kas9 \[lin-39::mNG::AID\])* or *unc-3 (ot837 \[unc-3::mNG::AID\])* ([@bib39]) were crossed with ieSi57 \[*eft-3prom::tir1*\] animals that express TIR1 ubiquitously. Auxin (indole-3-acetic acid \[IAA\]) was dissolved in ethanol (EtOH) to prepare 400 mM stock solutions which were stored at 4°C for up to one month. NGM agar plates with fully grown OP50 bacteria were coated with auxin solution to a final concentration of 4 mM, and allowed to dry overnight at room temperature. To induce protein degradation, worms of the experimental strains were transferred onto auxin-coated plates and kept at 20°C. As control, worms were transferred onto EtOH-coated plates instead. Auxin solutions, auxin-coated plates, and experimental plates were shielded from light.

Microscopy {#s4-7}
----------

Worms were anesthetized using 100 mM of sodium azide (NaN~3~) and mounted on a 4% agarose pad on glass slides. Images were taken using an automated fluorescence microscope (Zeiss, Axio Imager.Z2). Acquisition of several z-stack images (each \~1 µm thick) was taken with Zeiss Axiocam 503 mono using the ZEN software (Version 2.3.69.1000, Blue edition, RRID:[SCR_013672](https://scicrunch.org/resolver/SCR_013672)). Representative images are shown following max-projection of 1--8 µm Z-stacks using the maximum intensity projection type. Image reconstruction was performed using Image J software (RRID:[SCR_003070;](https://scicrunch.org/resolver/SCR_003070) [@bib68]).

Chromatin immunoprecipitation (ChIP) {#s4-8}
------------------------------------

ChIP assay was performed as previously described ([@bib87]; [@bib89]) with the following modifications. Synchronized *unc-3 (n3435); lin-39 (kas9 \[lin-39::mNG::3xFLAG::AID\]* worms at L1 stage were cultured on 10 cm plates seeded with OP50 at 20°C overnight. Early L3 worms were cross-linked and resuspended in FA buffer supplemented with protease inhibitors (150 mM NaCl, 10 μl 0.1 M PMSF, 100 μl 10% SDS, 500 μl 20% N-Lavroyl sarsosine sodium, 2 tablets of cOmplete ULTRA Protease Inhibitor Cocktail \[Roche Cat.\# 05892970001\] in 10 ml FA buffer). The sample was then sonicated using a Covaris S220 at the following settings: 200 W Peak Incident Power, 20% Duty Factor, 200 Cycles per Burst for 60 s. Samples were transferred to centrifuge tubes and spun at the highest speed for 15 min. The supernatant was transferred to a new tube, and 5% of the material was saved as input and stored at −20°C. Twenty (20) μl of equilibrated anti-FLAG M2 magnetic beads (Sigma-Aldrich M8823) were added to the remainder. The *lin-39 (kas9 \[lin-39::mNG::3xFLAG::AID\])* CRIPSR-generated allele was used in order to precipitate the immunocomplex comprising the endogenous LIN-39 protein and the bound DNA. The immunocomplex was incubated and rotated overnight at 4°C. On the next day, the beads were washed at 4°C twice with 150 mM NaCl FA buffer (5 min each), once with 1M NaCl FA buffer (5 min). The beads were transferred to a new centrifuge tube and washed twice with 500 mM NaCl FA buffer (10 min each), once with TEL buffer (0.25 M LiCl, 1% NP-40, 1% sodium deoxycholate, 1 mM EDTA, 10 mM Tris-HCl, pH 8.0) for 10 min, twice with TE buffer (5 min each). The immunocomplex was then eluted in 200 μl elution buffer (1% SDS in TE with 250 mM NaCl) by incubating at 65°C for 20 min. The saved input samples were thawed and treated with the ChIP samples as follows. One (1) μl of 20 mg/ml proteinase K was added to each sample and the samples were incubated at 55°C for 2 hr and then at 65°C overnight (12--20 hr) to reverse cross-link. The immunoprecipitated DNA was purified with Ampure XP beads (A63881) according to manufacturer's instructions. Library preparation and Illumina sequencing was performed at the Genomics Core facility of the University of Chicago. The LIN-39 ChIP-Seq data on wild-type animals were generated by the modENCODE project (RRID:[SCR_006206](https://scicrunch.org/resolver/SCR_006206)).

Real-time quantitative PCR (qPCR) analysis of ChIP DNA {#s4-9}
------------------------------------------------------

ChIP was performed on *unc-3 (n3435); wgIs18 (lin-39 ^fosmid^::GFP)* animals as described above. qPCR analysis of ChIP DNA was performed to probe enrichment of predicted LIN-39 binding sites at four target genes (*acr-2, dbl-1, unc-129, lin-39*). Three biological replicates were included. The primers used are provided in 5'−3' orientation: *acr-2* LIN-39 site (FRW: acattcgcaccaacaaagcg; RVS: aaaggacggacccaacagac), *acr-2* 3' UTR (FRW: tttcagcgccacatgtgtttg; RVS: attgcctagtgattctgagtagagg), *dbl-1* LIN-39 site (FRW: gcacaatccctcgggatcaa; RVS: TAAGTTTTGCGCTGCTGCTG), *dbl-1* 3' UTR (FRW: atacccgcttctatgtcgcc; RVS: ccgtgacacattgcaccaaa), *unc-129* LIN-39 site (FRW: attcgtgtctcgcagggaac; RVS: atagaggaaccggcaaaggtg), *unc-129 3' UTR* (FRW: ttctgtctgtacatcttccctacc; RVS: tttgccaagaaacaaagagagcag), lin-39 LIN-39 site (FRW: gacgtctccctctttctcctc; RVS: tccgctttctgagactccac), *lin-39* 3'UTR (FRW: gttcaagaaaaatattgtgcgttcc; RVS: catttttcgctcgaactgatgga). The amplification was conducted in a QuantStudio three using the Power SYBR Green PCR Master Mix (ThermoFisher Cat.\# 4367659), with the following program: Step 1: 95°C for 10 min; Step 2: 95°C for 15 s; Step 3: 60°C for 1 min. Repeat steps 2--3 for 40 times.

Motor neuron identification {#s4-10}
---------------------------

Motor neuron (MN) subtypes were identified based on combinations of the following factors: (a) co-localization with fluorescent markers with known expression pattern, (b) invariant cell body position along the ventral nerve cord, or relative to other MN subtypes, (c) MN birth order, and (d) number of MNs that belong to each subtype.

Bioinformatic analysis {#s4-11}
----------------------

To predict the UNC-3 binding site (COE motif) in the *cis*-regulatory region of *unc-129, del-1, acr-2, unc-77* and *slo-2*, we used the MatInspector program from Genomatix ([@bib10]) (RRID:[SCR_008036](https://scicrunch.org/resolver/SCR_008036)). The Position Weight Matrix (PWM) for the LIN-39 binding site is catalogued in the CIS-BP (Catalog of Inferred Sequence Binding Preferences database) ([@bib82]). To identify putative LIN-39 sites on the *cis*-regulatory regions of *unc-129, del-1, acr-2, unc-77, slo-2, oig-1,* and *ser-2,* we used FIMO (Find Individual Motif Occurrences)([@bib25]), which is one of the motif-based sequence analysis tools of the MEME (Multiple Expectation maximization for Motif Elicitation) bioinformatics suite (<http://meme-suite.org/>). To predict the binding site for the transcription factor UNC-30, we performed FIMO analysis using the UNC-30 binding motif (WNTAATCHH) described in [@bib14]. The p-value threshold for the analysis was set at p\<0.005.

Automated worm tracking {#s4-12}
-----------------------

Worms were maintained as mixed stage populations by chunking on NGM plates with *E. coli* OP50 as the food source. The day before tracking, 30--40 L4 larvae were transferred to a seeded NGM plate and incubated at 20°C for approximately 24 hr. Five adults are picked from the incubated plates to each of the imaging plates (see below) and allowed to habituate for 30 min before recording for 15 min. Imaging plates are 35 mm plates with 3.5 mL of low-peptone (0.013% Difco Bacto) NGM agar (2% Bio/Agar, BioGene) to limit bacteria growth. Plates are stored at 4°C for at least two days before use. Imaging plates are seeded with 50 μl of a 1:10 dilution of OP50 in M9 the day before tracking and left to dry overnight with the lid on at room temperature.

Behavioral feature extraction and analysis {#s4-13}
------------------------------------------

All videos were analyzed using Tierpsy Tracker ([@bib34]) to extract each worm's position and posture over time. These postural data were then converted into a set of behavioral features as previously described ([@bib35]). From the total set of features, we only considered 48 that are related to midbody posture and motion, as well as the midbody width (see [Supplementary file 3](#supp3){ref-type="supplementary-material"} for feature descriptions and their average values for each strain). For each strain comparison, we performed unpaired two-sample t-tests independently for each feature. The false discovery rate was controlled at 5% across all strain and feature comparisons using the Benjamini Yekutieli procedure ([@bib41]). The p-value threshold to control the false discovery rate at 0.05 is 0.0032.

Cloning, western blot, and immunoprecipitation {#s4-14}
----------------------------------------------

UNC-3, and LIN-39 cDNAs were cloned into the mammalian expression vectors pcDNA 3.1(+)- C-Flag plasmid and the pcDNA 3.1(+)-N-Myc plasmid by GeneScript, to generate C-terminus Flag-tagged UNC-3 and N-terminus Myc-tagged LIN-39. The constructs were verified by sequencing at the sequencing core facility of University of Chicago. The tagged proteins were expressed in HEK293 cells. Protein expression was detected by standard western blot. Expression of Myc tagged LIN-39 was detected using anti-Myc (Abcam, \#ab9106, RRID:[AB_307014](https://scicrunch.org/resolver/AB_307014)), expression of Flag-tagged UNC-3 in the total cell lysate was detected using mouse anti-Flag (Sigma, \#F3165, RRID:[AB_259529](https://scicrunch.org/resolver/AB_259529)), expression of Flag-tagged UNC-3 in the IP was detected using rabbit anti-Flag (Sigma, \#SAB4301135, RRID:[AB_2811010](https://scicrunch.org/resolver/AB_2811010)). Immunoprecipitation of Flag-tagged UNC-3 was performed using Flag antibody coated beads (Sigma, \#A2220). For the IP, the 'Clean-Blot IP Detection Reagent' (Thermo Fisher, \#21230) was used as secondary antibody.

Quantification of fluorescence intensity {#s4-15}
----------------------------------------

Images of worms carrying the *lin-39::mNG::3xFLAG::AID* or *unc-3::mNG:: 3xFLAG::AID* alleles were taken on the same slide with the same camera settings at the same development stage. Acquisition of four z-stack images (each 0.53 µm thick) covering the middle portion of targeted MN cell bodies was taken with Zeiss Axiocam 503 mono using the ZEN software (Version 2.3.69.1000, Blue edition, RRID:[SCR_013672](https://scicrunch.org/resolver/SCR_013672)). Image reconstruction was performed using Image J software following average-projection the Z-stacks using the average intensity projection protocol. The chosen cells for quantification of mNG fluorescence intensity for both genotypes are the same 10 cholinergic MNs: AS2, DB3, DA2, VA3, VB4, AS3, DA3, VA4, VB5 and DB4. Targeted cell areas were manually selected with minimum background as region of interest (ROI) and the total fluorescence Intensity was measured, calculated, and then represented by Image J as Integrated Density -- IntDen (ROI). Background was additionally selected and IntDen (Background) was calculated. The net fluorescence intensity increase is represented as NeIncr = IntDen(ROI)/Area(ROI) -- IntDen (Background)/Area(Background). 12 NetIncrs of both genotypes were calculated and data were normalized by dividing the Median of NetIncr (*lin-39::mNG::3xFLAG::AID*) for better contrast and presented as arbitrary units (a.u).

Statistical analysis {#s4-16}
--------------------

For data quantification, graphs show values expressed as mean ± standard deviation (STDV). The statistical analyses were performed using the unpaired *t*-test (two-tailed). Calculations were performed using the Evan's Awesome A/B Tools online software (<https://www.evanmiller.org/ab-testing/t-test.html>). Differences with p\<0.05 were considered significant. Quantifications are provided in the form of box-and-whisker plots (Tukey boxplot) with individual data point dot-plotted. In all boxplots, middle horizontal line represents the median value (equals to Q2). The box illustrates the interquartile range (IQR), that is from Q1 to Q3. The upper limit indicates either the maximum value if maximum \<Q3 + 1.5\*IQR, or the value that is not higher than Q3 + 1.5\*IQR. Similarly, the lower limit indicates either the minimum value or the value that is not lower than Q1 - 1.5\*IQR.
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###### UNC-3 binding sites (COE motifs) are not found in the *cis*-regulatory region of VD- and VC-expressed terminal identity genes.

###### LIN-39/Hox targets in cholinergic and GABAergic (VD) motor neurons.

Asterisk (\*) highlights novel LIN-39 targets; N. D: Not Determined. The selected *cis*-regulatory regions are LIN-39 ChIP-seq peaks that fall within the DNA sequence used for our reporter gene constructs (except for *del-1*). The UNC-3 binding sites (COE motifs 23 bp) have been previously described in [@bib42]. The LIN-39 binding sites were predicted by a FIMO search (p\<0.005). The UNC-30 binding site on *ser-2* locus was predicted by a FIMO search. The UNC-30 site on *oig-1* was experimentally validated in [@bib31].

###### Locomotion features assessed by automated worm tracking analysis.

Data availability {#s7}
=================

All data generated or analysed during this study are included in the manuscript and supporting files.
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**Acceptance summary:**

Your paper establishes the molecular mechanism used to determine and maintain terminal identity of cholinergic motor neurons in *C. elegans*. Your demonstration of the dual function of UNC-3 (Collier/Ebf) in directly promoting identity features of cholinergic motor neurons and in preventing terminal features of other ventral cord neuron types is striking. The role of the Hox protein LIN-39 that interacts with UNC-3 explains this dual role. Your data therefore shows that UNC-3 and LIN-39 co-activate terminal identity features of cholinergic motor neurons.

**Decision letter after peer review:**

Thank you for submitting your article \"A terminal selector prevents a Hox transcriptional switch to safeguard motor neuron identity throughout life\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Marianne Bronner as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

The general opinion of the reviewers is that the paper represents an important contribution to the field and presents concepts that should be of general interest to those studying neural specification in general and production of neurotransmitters in particular. However, while the regulatory network is clearly presented in the paper, there are some significant questions that remain and need to be addressed before the paper can be considered for publication.

In particular, a technical problem appears to be in the ChIP-PCR that you performed. It seems that are available ChIP-seq data that would be more valuable if they are of quality. If not, you should sequence your ChIP with Lin-39 and redo them in a *unc-3* mutant. This should also complemented by a detailed description of the *unc-3* phenotype, as suggested by reviewer \#2.

The other significant issue resides with the biochemistry in order to elucidate how these proteins interact with the promoters to regulate cell fate and neurotransmitters. The interaction between Lin39 and Unc-3 should be clarified.

Furthermore, the paper would gain by being presented in a simpler way so it would reach a wider audience. We also ask that you remove unsupported claims, as described by the reviewers below.

Reviewer \#1:

The manuscript by Feng et al. examines mechanisms through which UNC-3 transcription factor induces expression of genes expressed in cholinergic motor neurons while at the same time it suppresses expression of VD GABAergic motor neuron markers. The study provides a detailed genetic dissection of this problem, concluding that derepression of VD identity in the absence of UNC-3 is dependent on LIN-39 transcription factor. Interestingly, UNC-3 does not repress LIN-39 transcriptionally, instead it diverts its activity from VD target genes to cholinergic VNC motor neuron identity genes. The authors then investigate whether LIN-39 is sequestered away from VD enhancers by UNC-3 to regulatory elements associated with cholinergic motor neuron genes, as has been suggested for many other transcription factors (e.g. Mef2D-Crx interactions in retina (Andzelm et al., 2015) or Isl1-Lhx3/Onecut1 interaction in mammalian motor neurons (Rhee et al., 2016)). However, biochemical tests do not support this model. The authors do not detect physical interaction between UNC-3 and LIN-39, and they suggest that LIN-39 in not a limiting factor as it is not displaced from its binding sites in the absence of UNC-3. At the same time, they contradict this conclusion by demonstrating that VD genes can be induced in the context of cholinergic motor neurons by simply increasing the dosage of LIN-39.

While the genetic analysis and characterization of mutant phenotypes is rigorous and convincing, I am less convinced by the chromatin immunoprecipitation data. Mainly, their ChIP-PCR analysis lacks proper negative controls (regions not bound by transcription factors). More importantly, ChIP-PCR is an inferior method for the analysis of transcription factor binding, prone to false positives and general misinterpretation of transcription factor binding data. Surprisingly, the authors take minimal advantage of the existing LIN-39 ChIP-seq data. If they believe the data are of good quality, they should rely on them to demonstrate binding to the discovered enhancers. If they believe that their data are better, they should sequence their material and include it in the manuscript. In addition, they should perform ChIP-seq analysis in *unc-3* animals to substantiate their claim that LIN-39 does not relocate from cholinergic enhancers to VD enhancers.

Overall, the manuscript is long and dense. The authors should make an attempt to streamline it and simplify it by focusing on the most important points.

In several places the authors state that a \"uniform\" population of cholinergic motor neurons gives rise to distinct VC and VD neuronal identities in *unc-3* animals. However, VNC cholinergic neurons are not a uniform population as they are composed of five different subtypes. Furthermore, the data clearly show that VC neurons are mainly derived from AS neurons while VD neurons are primarily derived from DA/B and VA/B neurons.

It appears that all tested sites listed in Supplementary file 2 show LIN-39 binding -- this raises the concern that the ChIP is globally enriched for DNA and any tested regions will be positive. It is essential to include negative genomic regions in ChIP-PCR experiments and in general it would be preferable to perform ChIP-seq analysis. The authors should show existing LIN-39 ChIP-seq tracks for each of the examined regulatory regions.

The authors conclude that LIN-39 is not a limiting factor. How do they interpret the LIN-39 overexpression results that leads to the activation of VD markers in VNC cholinergic neurons?

The authors should provide better description of LIN-39 expression pattern and describe its mutant phenotype in detail.

The authors present their model as revealing completely new mechanisms of regulation of gene expression. However, cell type-specific transcription factor binding to distinct enhancers is a well-known phenomenon with several publications detailing how interactions with different transcription factors result in relocation of TF complexes from one region to another. The authors should present their work in the context of this literature.

Reviewer \#2:

This work from the Kratsios lab aims to understand how neurons acquire and importantly maintain their fate. It takes advantage of the well-studied and characterized *C. elegans* nervous system, focusing on motor neurons. The wealth of genetic, cellular and molecular tools makes *C. elegans* an appropriate model system. Additionally, motor neurons are particularly interesting cell type because they acquire and maintain a generic motor neuron fate, plus an appropriate motor neuron subtype. Thus, the topic is relevant and addressed with appropriate tools.

Previous work, with a significant contribution by Kratsios, established that the motor neuron terminal selector *unc-3* directly activates and maintains a sub-set of motor neuron fates. These findings are confirmed and expanded in this manuscript. Of note, the degron experiment presented here is a nice confirmation of this hypothesis. Similar to other species, Hox genes coordinate their activity to establish distinct motor neurons fates. In this work, *lin-39* recovered though a screen and *mab-5* as candidate Hox genes regulating terminal genes. Again, there is a nice confirmation of this *lin-39* as terminal selector hypothesis by ChIP and the Lin-39 degron allele.

One interesting take home from this work is the underlying gene regulatory network. Not all motor neurons acquire the same \"default state\" upon *unc-3* removal and divide themselves into 3 groups based on the set of analyzed makers: VD, VC or undetermined. These results suggest a heterogeneous underlying regulatory network controlling motor neuron fate that might be canalized by *unc-3* activity. Because it is at the crux of the phenotype, the author should be very clear describing the phenotype. Is this an expressivity issue or it is 100% penetrant with high expressivity in always the same cells across animals? or is not fully penetrant or with variable expressivity across motor neurons? Depending on the phenotype, combining all motor neurons in a single group might not be the appropriate data representation. Additionally, it will significantly change the conclusions that can be derived from the data.

At large, this work revolves around the combinatorial control of cell fate. It further dissects the *unc-3*/Hox dependent regulation of motor neuron fate. Activation of neuronal type-specific features and preventing the expression of different cell fates is a well-described transcription factor activity during chick and mouse motor neuron development. I am confused by the strong emphasis on \"transcriptional switch\". It is stressed as a novel insight but there is not tangible mechanistic evidence for it. Moreover, the phenotypes are changes in gene expression with repression and activation of terminal genes, not a complete switch of fates as far as I can tell. At the mechanistic level of gene regulation by transcription factors, there is no evidence of *unc-3* or *lin-39* switching binding targets or DNA motif preference. Additionally, transcription factor target switch by changing binding partners has been extensively described, even during motor neuron development.

Finally, there is a trend to make claims that are not strictly supported by the data or a lack of precision describing phenotypes. In my opinion, this work has a few confirmatory results, the significant claim is not supported by the data and thus it does not provide a significant conceptual nor technical leap for *eLife*.

Reviewer \#3:

This paper investigated the molecular mechanism used to determine and maintain terminal identity features of cholinergic motor neurons in the *C. elegans* ventral nerve cord. The authors showed dual function of the terminal selector UNC-3 (Collier/Ebf) in directly promoting identity features of cholinergic motor neurons and indirectly preventing expression of terminal features of three other ventral cord neuron types (VD, VC, CA). Through an unbiased genetic screen, the authors identified the Hox protein LIN-39 (Scr/Dfd/Hox4-5) to be required for ectopic expression of VD and VC features in *unc-3* mutants. In summary, the data presented in the paper supports the dual role of UNC-3: UNC-3 and LIN-39 directly co-activate terminal identity features of cholinergic motor neurons; UNC-3 antagonizes the LIN-39\'s ability of activating terminal features of alternative neuronal identities.

The paper is well written. However, some points should be addressed or clarified.

\- It has been previously shown that *unc-3* and *lin-39* in act synergistically to activate expression of cholinergic motor neuron terminal identity genes (Kratsios et al., 2017). This study identified a new role of *unc-3* in antagonizing the LIN-39\'s function of activating terminal features of alternative neuronal identities. The authors should perform additional experiments to provide a mechanistic insight into how UNC-3 prevents LIN-39-mediated transcriptional switch for inducing expression of alternative identity features.

\- The authors showed data to indicate that *lin-39* and *unc-30* act in parallel to co-activate VD terminal identity genes. However, the authors also showed that ectopic expression of VD markers is not dependent on UNC-30. The contradictory results should be discussed. Does the data suggest that *lin-39* acts with yet-to-be identified factor(s) to activate ectopic expression of VD features in *unc-3* mutants?

10.7554/eLife.50065.sa2

Author response

> The general opinion of the reviewers is that the paper represents an important contribution to the field and presents concepts that should be of general interest to those studying neural specification in general and production of neurotransmitters in particular. However, while the regulatory network is clearly presented in the paper, there are some significant questions that remain and need to be addressed before the paper can be considered for publication.
>
> In particular, a technical problem appears to be in the ChIP-PCR that you performed. It seems that are available ChIP-seq data that would be more valuable if they are of quality. If not, you should sequence your ChIP with Lin-39 and redo them in a unc-3 mutant. This should also complemented by a detailed description of the unc-3 phenotype, as suggested by reviewer \#2.
>
> The other significant issue resides with the biochemistry in order to elucidate how these proteins interact with the promoters to regulate cell fate and neurotransmitters. The interaction between Lin39 and Unc-3 should be clarified.
>
> Furthermore, the paper would gain by being presented in a simpler way so it would reach a wider audience. We also ask that you remove unsupported claims, as described by the reviewers below.

We thank the reviewers for their constructive comments. The revised manuscript addresses all of the comments and, as suggested, contains: (a) available LIN-39 ChIP-seq data, (b) new data we generated for LIN-39 ChIP-seq in *unc-3* mutants, (c) new ChIP-PCR data with appropriate negative controls, (d) a detailed description of *unc-3* and *lin-39* mutant phenotypes and expression patterns, (e) new data that help clarify how LIN-39 interacts with *cis*-regulatory elements to drive expression of terminal identity genes in wild-type cholinergic MNs and VD-specific genes in *unc-3*-depleted MNs. Lastly, we have corrected two claims (cholinergic MNs are not a uniform population, LIN-39 is a rate-limiting factor) and streamlined the text throughout, so that the paper would reach a wider audience.

> Reviewer \#1:
>
> The manuscript by Feng et al. examines mechanisms through which UNC-3 transcription factor induces expression of genes expressed in cholinergic motor neurons while at the same time it suppresses expression of VD GABAergic motor neuron markers. The study provides a detailed genetic dissection of this problem, concluding that derepression of VD identity in the absence of UNC-3 is dependent on LIN-39 transcription factor. Interestingly, UNC-3 does not repress LIN-39 transcriptionally, instead it diverts its activity from VD target genes to cholinergic VNC motor neuron identity genes. The authors then investigate whether LIN-39 is sequestered away from VD enhancers by UNC-3 to regulatory elements associated with cholinergic motor neuron genes, as has been suggested for many other transcription factors (e.g. Mef2D-Crx interactions in retina (Andzelm et al., 2015) or Isl1-Lhx3/Onecut1 interaction in mammalian motor neurons (Rhee et al., 2016)). However, biochemical tests do not support this model. The authors do not detect physical interaction between UNC-3 and LIN-39, and they suggest that LIN-39 in not a limiting factor as it is not displaced from its binding sites in the absence of UNC-3. At the same time, they contradict this conclusion by demonstrating that VD genes can be induced in the context of cholinergic motor neurons by simply increasing the dosage of LIN-39.
>
> While the genetic analysis and characterization of mutant phenotypes is rigorous and convincing, I am less convinced by the chromatin immunoprecipitation data. Mainly, their ChIP-PCR analysis lacks proper negative controls (regions not bound by transcription factors). More importantly, ChIP-PCR is an inferior method for the analysis of transcription factor binding, prone to false positives and general misinterpretation of transcription factor binding data. Surprisingly, the authors take minimal advantage of the existing LIN-39 ChIP-seq data. If they believe the data are of good quality, they should rely on them to demonstrate binding to the discovered enhancers. If they believe that their data are better, they should sequence their material and include it in the manuscript. In addition, they should perform ChIP-seq analysis in unc-3 animals to substantiate their claim that LIN-39 does not relocate from cholinergic enhancers to VD enhancers.

We completely agree with the reviewer. Our new set of experiments helped paint a clearer picture of the molecular mechanism underlying the dual role of UNC-3 and support the conclusion that LIN-39 is indeed the rate-limiting factor.

By using available LIN-39 ChIP-seq data, it is evident that LIN-39 directly binds to *cis*-regulatory elements of cholinergic MN identity genes (new Figure 5C, Figure 5---figure supplement 1), corroborating our genetic analysis. By performing ChIP-seq for LIN-39 in *unc-3* mutants, we found that LIN-39 binding is dramatically decreased to these gene loci (new Figure 5C, Figure 5---figure supplement 1). Our new RT-PCR data, in *unc-3* mutants, on these cholinergic MN terminal identity genes further corroborated the ChIP-seq data (new Figure 5---figure supplement 1). Together, these findings suggest that LIN-39 binding on cholinergic MN identity genes depends on UNC-3, raising the possibility that UNC-3 recruits LIN-39 (or diverts LIN-39 activity away) from VD gene promoters. Supporting this scenario, ectopic expression of UNC-3 in VD neurons results in decreased expression of *lin-39*-dependent VD-specific markers (Figure 9C, Figure 9---figure supplement 2C). We thank the reviewer for the suggestion to rely on ChIP-seq data and include additional negative controls (3'UTR) in our RT-PCR analysis, enabling us to clarify the molecular mechanism.

In addition, we quantified the endogenous expression levels of *lin-39* and found it to be expressed at relatively low levels in cholinergic MNs compared to *unc-3* levels, further supporting the conclusion that LIN-39 is the rate-limiting factor. This conclusion is further supported by our gene dosage experiments for *unc-3* and *lin-39* (Figure 9B-C). For example, over-expression of LIN-39 in cholinergic MNs results in activation of VD-specific genes (Figure 9C). Together, our results suggest that the collaboration of UNC-3 with LIN-39 on cholinergic MN identity gene promoters exhausts the limited amount of LIN-39 in the cell and VD genes remain off. However, LIN-39 is released from cholinergic MN gene promoters in the absence of UNC-3 and activates VD genes.

Lastly, we now provide evidence that LIN-39 acts through distinct *cis*-regulatory elements to activate the same VD-specific gene (*oig-1*) in wild-type VD neurons versus VD-like neurons of *unc-3* mutants (new Figure 8, please also see our sixth response to reviewer \#2). We have revised the text to include these new findings (Results, subsection "LIN-39 acts through distinct cis-regulatory elements to control *oig-1* expression in VD and VD-like motor neurons") and also discuss our findings in the context of the Mef2D-Crx and Isl1-Lhx3/Onecut1 studies mentioned by the reviewer (Introduction; Discussion).

> Overall, the manuscript is long and dense. The authors should make an attempt to streamline it and simplify it by focusing on the most important points.

We carefully went through the manuscript. The revised text now focuses on the most important points raised in Introduction: (a) post-embryonic requirement of UNC-3 and LIN-39, and (b) dissection of the UNC-3/LIN-39 molecular mechanism of action. In an attempt to streamline and simplify, we carefully edited the text throughout and removed several redundant sentences, as well as an entire paragraph in Discussion.

> In several places the authors state that a \"uniform\" population of cholinergic motor neurons gives rise to distinct VC and VD neuronal identities in unc-3 animals. However, VNC cholinergic neurons are not a uniform population as they are composed of five different subtypes. Furthermore, the data clearly show that VC neurons are mainly derived from AS neurons while VD neurons are primarily derived from DA/B and VA/B neurons.

We thank the reviewer for this comment. We have corrected this statement in Introduction and Discussion.

> It appears that all tested sites listed in Supplementary file 2 show LIN-39 binding -- this raises the concern that the ChIP is globally enriched for DNA and any tested regions will be positive. It is essential to include negative genomic regions in ChIP-PCR experiments and in general it would be preferable to perform ChIP-seq analysis. The authors should show existing LIN-39 ChIP-seq tracks for each of the examined regulatory regions.

Prompted by this comment, we obtained and analyzed the LIN-39 ChIP-seq data (from modENCODE), which were performed on wild-type animals at L3, a stage at which the defects we discovered on cholinergic MNs of *lin-39* mutants are present. In the revised manuscript, we include LIN-39 ChIP-seq tracks for all LIN-39 targets (*unc-129, del-1, acr-2, unc-77, slo-2, oig-1, ser-2, flp-11*) revealed from our genetic analysis and shown in Supplementary file 2. This data (Figure 5C, Figure 8, Figure 5---figure supplement 1) show clear LIN-39 binding peaks in the *cis*-regulatory region of all these genes, and no peaks at regions that are normally not bound by transcription factors (e.g., 3' UTR). Moreover, the LIN-39 ChIP-seq peaks align with the LIN-39 sites that we identified bioinformatically based on the LIN-39 consensus motif (Supplementary file 2).

Importantly, we functionally tested the requirement of one LIN-39 binding site in the promoter of *oig-1*, a gene normally activated by LIN-39 in VD neurons. Mutation of this site in the context of transgenic *oig-1* reporter animals carrying a minimal *cis*-regulatory fragment (*oig-1_125bp ^LIN-39\ site\ MUT::RFP^*) led to a significant decrease in *rfp* expression in VD neurons (Figure 8A-B). These findings indicate that our functional testing of LIN-39 sites is in agreement with the binding pattern of LIN-39 on the genome based on published ChIP-seq data.

> The authors conclude that LIN-39 is not a limiting factor. How do they interpret the LIN-39 overexpression results that leads to the activation of VD markers in VNC cholinergic neurons?

Our new ChIP-seq data helped clarify the molecular mechanism, as discussed above. The revised manuscript now states that LIN-39 is a rate-limiting factor (Results, subsection "The LIN-39-mediated transcriptional switch depends on UNC-3 and LIN-39 levels"; Discussion, subsection "UNC-3 determines the function of the rate-limiting factor LIN-39/Hox in cholinergic motor neurons").

> The authors should provide better description of LIN-39 expression pattern and describe its mutant phenotype in detail.

We carried out a detailed analysis to describe with single-cell resolution the expression pattern for the mid-body Hox gene *lin-39* in MNs. Using two reporters (a CRISPR-based and a fosmid \[\~30kb genomic clone\]-based reporter) that faithfully recapitulate the endogenous *lin-39* expression pattern, we found that LIN-39 is co-expressed with UNC-3 in 28 cholinergic MNs (from AS2 at the anterior end of the VNC to DB7 at the posterior end). Importantly, this number is in close agreement with the total number of VD-like (12.1 ± 2.6 \[mean ± STDV\]) and VC-like (10.5 ± 3.7 \[mean ± STDV\]) cells observed in *unc-3* mutants. A summary of *lin-39* expression in cholinergic MNs is shown in Figure 4E and Figure 4---figure supplement 2.

Following a similar analysis, we determined the expression of *lin-39* in GABAergic neurons of the nerve cord (seven VD \[VD3-VD9\] and four DD \[DD2-DD5\] express *lin-39)*. These data are presented in Figure 7A and Figure 4---figure supplement 2. Lastly, we found *lin-39* to be expressed in all six sex-specific VC neurons. Together, this analysis shows that *lin-39* is expressed in every motor neuron located between AS2 and VD9 (Figure 4E, 7A), consistent with the typical, region-specific expression pattern of Hox genes across species.

The function of *lin-39* in cholinergic and GABAergic MNs was largely unknown. Our manuscript describes multiple terminal identity genes under the direct control of LIN-39 in cholinergic and VD motor neurons. Since these genes code for proteins critical for neuronal function (e.g., ion channels, NT receptor, neuropeptides), it is conceivable that loss of expression of these genes leads to the observed locomotion defects of *lin-39* mutants (Discussion). In the revised manuscript, we describe in detail the *lin-39* mutant phenotype in Results, and made new schematics to summarize the *lin-39* effects on terminal identity in Figures 5D and 7F. In addition, we mention in Results that all MNs that control *C. elegans* locomotion (cholinergic and GABA) are normally generated in *lin-39* mutants. However, the six hermaphrodite-specific neurons (VC) that control egg laying do not survive in *lin-39* null mutants, precluding us from testing in these animals whether LIN-39 is acting at later stages of their development. We bypassed the VC survival issue by using our auxin-inducible *lin-39* allele, and found that *lin-39* is required to maintain the expression of VC-specific terminal identity genes, similar to our findings in cholinergic and GABAergic neurons (Results).

> The authors present their model as revealing completely new mechanisms of regulation of gene expression. However, cell type-specific transcription factor binding to distinct enhancers is a well-known phenomenon with several publications detailing how interactions with different transcription factors result in relocation of TF complexes from one region to another. The authors should present their work in the context of this literature.

In the revised manuscript (Introduction; Discussion), we now present our findings in the context of previous literature mentioned by reviewer \#1 (Andzelm et al., 2015; Rhee et al., 2016) and reviewer \#2 (papers on LIM homeodomain TFs Islet1 and Chx10 in of motor neurons and V2 interneurons, respectively). We thank both reviewers for pointing out these important papers. All these studies focus on the combinatorial logic through which TFs control neuronal cell fate. However, there are several noteworthy differences between these papers and our study, as detailed below.

First, the post-embryonic requirement for the TFs mentioned in these previous studies was not tested. Hence, it remained unclear whether the proposed mechanisms operate transiently during development, or continuously throughout life. In fact, Rhee et al. proposed that, in nascent (very young) mammalian MNs in vitro, a dynamic relay of transient enhancers bound by stage-specific TFs controls cell identity. By temporally inactivating UNC-3 and LIN-39 at post-embryonic stages (Figures 3, 6, 7C) in mature MNs, we provide evidence that both of these proteins are continuously required to safeguard motor neuron terminal identity. Importantly, temporal inactivation of the Hox protein LIN-39 was performed in both WT and *unc-3* mutant backgrounds, indicating that LIN-39 is continuously required to: (i) activate cholinergic MN terminal identity genes in the presence of UNC-3, and (ii) activate VD genes in the absence of UNC-3. Lastly, these experiments advanced our understanding of Hox protein function in the nervous system by uncovering that LIN-39/Hox is required to maintain MN identity (Discussion).

Second, certain aspects of our findings are similar to the seminal study by Andzelm et al. in mouse photoreceptors, indicating an evolutionary conservation of the molecular principle we discovered in *C. elegans*. Andzelm et al. found that CRX and MEF2D co-operate to activate expression of retina-specific enhancers in photoreceptor cells. CRX recruits MEF2D to these retina-specific enhancers, thereby preventing MEF2D to bind to other enhancers. However, this study did not address whether and how these "other enhancers" are controlled by MEF2D in other cell types. We provide a comprehensive analysis of LIN-39 not only in the context of cholinergic MNs where it cooperates with UNC-3, but also in the context of VD neurons where it cooperates with another terminal selector (UNC-30/Pitx). We refer to the Andzelm paper in the text (Introduction; Discussion).

Third, seminal work in the context of mouse and chick motor neurons has shown that different TF interactions result in relocation of TF binding from one region to the other. For example, Isl1, Lhx3 and NLI (also known as MN hexamer complex) bind to hemaxer response elements (HxRE) found in the *cis*-regulatory region of MN genes. In V2a interneurons, Lhx3 is not expressed and Isl1 and NLI form a tetrameric complex (V2 tetramer) that binds to tetramer response element (TeRE) upstream of V2a genes. However, the mechanism through which the MN hexamer and the V2 tetramer prevent expression of alternative identities relies on transcriptional repressors (Hb9, Chx10) downstream of these complexes. Although we cannot exclude the possibility that other, yet-to-be identified repressors may be activated by UNC-3 to prevent expression of alternative identities, our current data suggest a simple mechanism where LIN-39 is the rate-limiting factor present in limited amounts in cholinergic MNs. We present our findings in the context of the MN hexamer and V2a tetramer in Discussion (section entitled "*UNC-3 determines the function of the rate-limiting factor LIN-39/Hox in cholinergic motor neurons*").

> Reviewer \#2:
>
> This work from the Kratsios lab aims to understand how neurons acquire and importantly maintain their fate. It takes advantage of the well-studied and characterized C. elegans nervous system, focusing on motor neurons. The wealth of genetic, cellular and molecular tools makes C. elegans an appropriate model system. Additionally, motor neurons are particularly interesting cell type because they acquire and maintain a generic motor neuron fate, plus an appropriate motor neuron subtype. Thus, the topic is relevant and addressed with appropriate tools.
>
> Previous work, with a significant contribution by Kratsios, established that the motor neuron terminal selector unc-3 directly activates and maintains a sub-set of motor neuron fates. These findings are confirmed and expanded in this manuscript. Of note, the degron experiment presented here is a nice confirmation of this hypothesis.

We thank the reviewer for this comment, which gave us the opportunity to improve the manuscript and explain why our findings significantly expand previous work. As stated in Introduction, our article aims to address two important questions in the field: (a) How do neuron type-specific TFs control neuronal terminal identity? (b) Are these factors continuously required (from development to adult)?

Although previous work showed that UNC-3 is continuously required to activate terminal identity genes in *C. elegans* motor neurons, it was not known whether UNC-3 is continuously required to prevent expression of alternative identity genes. Given precedents in the literature describing that TFs can exert stage-specific functions and act transiently (e.g., Rhee et al., 2016), or even switch targets (e.g., Wyler et al., 2016), it was not a given that UNC-3 is continuously required to prevent expression of terminal identity genes for alternative neuronal identities (VD, VC, CA). Our auxin-inducible protein depletion experiments found this to be the case, providing strong evidence for a dual role of UNC-3 that takes place during development and post-embryonic life. Lastly, we provide key molecular insights into how UNC-3 prevents expression of alternative identity genes, i.e., by antagonizing the ability of the mid-body Hox protein LIN-39 to activate expression of alternative identity genes in cholinergic motor neurons. We have modified the text to describe better these findings (Results, Discussion).

> Similar to other species, Hox genes coordinate their activity to establish distinct motor neurons fates. In this work, lin-39 recovered though a screen and mab-5 as candidate Hox genes regulating terminal genes. Again, there is a nice confirmation of this lin-39 as terminal selector hypothesis by ChIP and the Lin-39 degron allele.

Indeed, seminal work in multiple model systems has revealed that Hox proteins control motor neuron fate. However, previous studies largely focused in the early steps of motor neuron development (e.g., progenitor specification, initial specification of motor neuron subtypes, establishment of motor neuron connectivity). In most model systems, the expression pattern and function of Hox proteins during the last steps of motor neuron development and post-embryonic life are largely unknown. In the revised manuscript, we discuss this knowledge gap and present our findings in the context of current Hox literature (Discussion, subsection: "Maintenance of terminal identity features: A new function of Hox proteins in the nervous system").

Prior to our work, it was unclear whether and how Hox proteins control expression of multiple terminal identity genes (e.g., ion channels, NT receptors, neuropeptides) in motor neurons, and, perhaps most important, whether Hox proteins are required at post-embryonic stages to maintain expression of terminal identity genes in motor neurons. We note that these 2 criteria (broad and direct regulation of terminal identity genes by a TF [and]{.ul} continuous requirement for a TF) must be fulfilled for a gene to be called a terminal selector, but previous studies did not address these criteria.

Our study identified multiple terminal identity genes as LIN-39 (Hox) targets in different motor neurons (six targets in cholinergic MNs, five targets in VD neurons, one target in VC neurons). Moreover, ChIP-seq for LIN-39 indicates direct control for these genes. Lastly, through embryonic and post-embryonic removal of LIN-39, we show that this Hox protein is required to induce during development and maintain throughout post-embryonic life motor neuron terminal identity.

> One interesting take home from this work is the underlying gene regulatory network. Not all motor neurons acquire the same \"default state\" upon unc-3 removal and divide themselves into 3 groups based on the set of analyzed makers: VD, VC or undetermined. These results suggest a heterogeneous underlying regulatory network controlling motor neuron fate that might be canalized by unc-3 activity. Because it is at the crux of the phenotype, the author should be very clear describing the phenotype. Is this an expressivity issue or it is 100% penetrant with high expressivity in always the same cells across animals? or is not fully penetrant or with variable expressivity across motor neurons? Depending on the phenotype, combining all motor neurons in a single group might not be the appropriate data representation. Additionally, it will significantly change the conclusions that can be derived from the data.

We thank the reviewer for this comment. In the revised manuscript, we have clarified that the *unc-3* mutant phenotype is fully penetrant (100%) with high expressivity in the same cells across animals (Results). This applies to both *unc-3* mutant populations of MNs (VD-like, VC-like).

For the VD-like population, ectopic expression of the VD terminal identity genes (*ser-2, oig-1*) is observed in all *unc-3* mutant animals (100% penetrance) (Figure 2A-B). To test whether this phenotype has high expressivity in the same cells across animals, we used fluorescent reporters (*ttr-39::mCherry, unc-47::mChOpti*), that are unaffected by loss of *unc-3* (Figure 2---figure supplement 1B), as landmarks for GABAergic nerve cord motor neurons (VD and DD) in wild-type (Figure 1---figure supplement 1), and *unc-3* (Figure 2---figure supplement 1B) mutants. Because the cell body position of cholinergic and GABAergic MNs is known in *C. elegans* and unaffected in *unc-3* mutants, we were able to unambiguously identify the *unc-3*-depleted motor neurons that acquire VD terminal identity features (VD-like). Through careful reporter analysis with single-cell resolution, we found the following MNs to consistently acquire expression of VD genes in *unc-3* mutants: DA4, DA5, DA7, DB5, DB6, DB7, VA3, VA4, VA5, VA6, VA9, VB4, VB9 (new Figure 2---figure supplement 1B).

For the VC-like population, ectopic expression of the VC terminal identity genes (*ida-1, glr-5, srb-16*) is observed in all *unc-3* mutant animals (100% penetrance) (Figure 2C-D). By performing the same type of single-cell analysis (new Figure 2---figure supplement 1B), we found that the following MNs consistently acquire expression of VC genes in *unc-3* mutants: VB7, AS2, AS3, AS4, AS5, AS6, AS7, AS8, AS9, AS10.

Lastly, we found that the VD-like and VC-like motor neurons represent distinct populations by generating *unc-3* mutants that carry a green marker for the VC terminal identity gene (*ida-1*) and a red marker for the VD terminal identity gene (*ser-2*). No significant overlap of the two markers was observed in *unc-3* mutants (Figure 2E-F).

> At large, this work revolves around the combinatorial control of cell fate. It further dissects the unc-3/Hox dependent regulation of motor neuron fate. Activation of neuronal type-specific features and preventing the expression of different cell fates is a well-described transcription factor activity during chick and mouse motor neuron development. I am confused by the strong emphasis on \"transcriptional switch\". It is stressed as a novel insight but there is not tangible mechanistic evidence for it.

Reviewer \#1 also commented on previous studies that describe activation of neuronal type-specific features and prevention of expression of different cell fates. Please see our sixth response to reviewer \#1. In brief, the revised manuscript now discusses our findings in the context of these previous studies.

Moreover, our new experiments provided additional mechanistic evidence for the observed transcriptional switch in the targets of LIN-39. In brief, LIN-39 and UNC-3 bind on enhancers of terminal identity genes in cholinergic MNs of wild-type animals (ChIP-seq data for LIN-39 binding on these genes shown in Figure 5C, Figure 5---figure supplement 1). In the absence of UNC-3, we observed a dramatic decrease of LIN-39 binding on these genes by performing LIN-39 ChIP-seq in *unc-3* mutants (Figure 5C, Figure 5---figure supplement 1). Guided by the LIN-39 ChIP-seq data, we performed a detailed *cis*-regulatory analysis for *oig-1*, a gene normally activated by LIN-39 in VD neurons of wild-type animals and ectopically expressed in "VD-like" neurons of *unc-3* mutants (new Figure 8). We deleted *cis*-regulatory regions that are normally bound by LIN-39 in the context of *oig-1* transgenic reporter animals. This analysis strongly suggests that LIN-39 acts through distinct *cis*-regulatory elements (that contain consensus LIN-39 binding sites, Supplementary file 2) to activate *oig-1* expression in VD versus VD-like cells of *unc-3* mutants. Lastly, we re-wrote a section of Discussion entitled "*UNC-3 determines the function of the rate-limiting factor LIN-39/Hox in cholinergic motor neurons*" to describe better the mechanism in light of the new data we obtained during the revision process.

> Moreover, the phenotypes are changes in gene expression with repression and activation of terminal genes, not a complete switch of fates as far as I can tell.

Yes, the phenotypes described in this manuscript concern changes in expression of terminal identity genes, whose protein products are critical for MN function (e.g., ion channels, neurotransmitter receptors, neuropeptides, etc.). In Results, we now clarify that the phenotype is not a complete fate switch (subsection "UNC-3 has a dual role in distinct populations of ventral nerve cord (VNC) motor neurons"). For example, the VD-like cells in *unc-3* do not acquire GABAergic neurotransmitter identity like the wild-type VD cells. Moreover, we mention in the Discussion subsection entitled"Limitations and lessons learned about the control of neuronal terminal identity", that is not possible to evaluate whether the VD-like cells in *unc-3* mutants acquire morphological characteristics of wild-type VD cells due to the strong axon guidance defects observed in *unc-3* mutants. Lastly, we discuss the implications of this incomplete cell fate switch for the evolution of novel cell types (Discussion).

> At the mechanistic level of gene regulation by transcription factors, there is no evidence of unc-3 or lin-39 switching binding targets or DNA motif preference.

Prompted by this comment, we conducted additional experiments that helped paint a clearer picture of the mechanism, now described in the revised manuscript. By using available LIN-39 ChIP-seq data, it is evident that LIN-39 directly binds to a host of terminal identity genes specific for cholinergic MNs (new Figure 5C, Figure 5---figure supplement 1), corroborating our genetic analysis. By performing ChIP-seq for LIN-39 in *unc-3* mutants, we detect that LIN-39 binding to these genes is dramatically decreased (new Figure 5C, Figure 5---figure supplement 1). Our new RT-PCR data, in *unc-3* mutants, on these cholinergic MN terminal identity genes further corroborated the ChIP-seq data (Figure 5---figure supplement 1). Together, these new data strongly suggest that LIN-39 and UNC-3 bind to *cis*-regulatory elements of cholinergic MN terminal identity genes and activate their transcription. In *unc-3* mutants, LIN-39 binding to these elements is decreased, presumably leading to increased availability of LIN-39 that results in activation of alternative identity genes (e.g., VD genes). Our new data support this possibility.

First, we quantified the levels of UNC-3 and LIN-39 proteins in cholinergic MNs, and found LIN-39 to be expressed at considerably lower levels compared to UNC-3, indicating that LIN-39 is a rate-limiting factor (new Figure 9A).

Second, we performed a comprehensive *cis*-regulatory analysis of the *oig-1* locus and found that LIN-39 acts through distinct *cis*-regulatory elements to activate *oig-1* in VD neurons versus VD-like neurons of *unc-3* mutants (new Figure 8).

In brief, LIN-39 and UNC-30/Pitx bind to the same *cis*-regulatory element of *oig-1* (called peak\#3 in Figure 8A). This element is required for *oig-1* expression in VD neurons of wild-type and *unc-3* mutants. This element contains a number of weak LIN-39 consensus sites (based on p value, Supplementary file 2), suggesting that UNC-30 stabilizes LIN-39 binding on these sites. However, this element (peak\#3) is not required for *oig-1* expression in VD-like cells of *unc-3* mutants (Figure 8A-B). Moreover, we identified a distal *cis*-regulatory element (300bp) of *oig-1* required for expression in VD-like cells. Interestingly, several strong consensus LIN-39 binding sites are found within this element (Supplementary file 2), suggesting that, in the absence of *unc-3*, LIN-39 no longer binds to cholinergic gene promoters and instead recognizes these strong consensus binding sites, presumably due to higher affinity to these sites.

We have revised the text (Results and Discussion) to include these new results, which are in complete agreement with our gene dosage experiments (Figure 9).

> Additionally, transcription factor target switch by changing binding partners has been extensively described, even during motor neuron development.

Reviewer \#1 made a similar comment. Please see our sixth response to reviewer \#1.

In addition, we now present our findings in the context of previous studies describing transcription factor target switch by changing binding partners. Specifically, we mention in Discussion previous work in mouse and chick motor neurons, where Islet1, Lhx3, and NLI form a hexameric complex (called MN hexamer) necessary to activate MN identity genes. In V2 interneurons, Islet1 is not expressed, and Lhx3 and NLI form a tetrameric complex (V2 tetramer) that recognizes distinct DNA sequences compared to MN hexamer, thus activating V2-specific genes. However, as mentioned in our sixth response to reviewer \#1 and Discussion, the underlying mechanism downstream of the MN hexamer and V2 tetramer involve a transcription repressor (Hb9, Chx10). Thus far, we found no evidence for a transcriptional repressor downstream of UNC-3.

Lastly, we cite two papers that involve transcription factor target switch by changing binding partners, one in *C. elegans* sensory neurons (Gordon and Hobert, 2015) and one in nascent mouse MNs in vitro (Rhee et al., 2016) (Introduction, second paragraph).

> Finally, there is a trend to make claims that are not strictly supported by the data or a lack of precision describing phenotypes.

We thank the reviewer for this comment, as it helped us improve the clarity of the manuscript.

We now describe in more detail the *unc-3* and *lin-39* mutant phenotypes in the Results. Please, note the inclusion of new schematics summarizing the *lin-39* mutant phenotype in Figures 5D and 7F. Lastly, we do recognize that two incorrect claims were made in the original version. Our new data helped us understand better the molecular mechanism and, in the revised manuscript, we have corrected these claims as shown below:

1\) LIN-39 is the rate-limiting factor (Results and Discussion).

2\) Cholinergic motor neurons are not a uniform population, as they can be subdivided into multiple subtypes. The incorrect statement is removed from Introduction and Discussion.

> In my opinion, this work has a few confirmatory results, the significant claim is not supported by the data and thus it does not provide a significant conceptual nor technical leap for eLife.

As mentioned above, the revised manuscript explains better why our study significantly advances our understanding of Hox gene function in the nervous system (Discussion). Moreover, an extensive set of new experiments (ChIP-seq for LIN-39 in *unc-3* mutants shown in Figure 5C, Figure 5---figure supplement 1; comprehensive *cis*-regulatory analysis of VD terminal identity gene *oig-1* shown in new Figure 8; quantification of LIN-39 levels shown in Figure 9A) helped clarify the molecular mechanism of action for UNC-3 and LIN-39. We hope that the revised manuscript now addresses the reviewer's concerns.

> Reviewer \#3:
>
> This paper investigated the molecular mechanism used to determine and maintain terminal identity features of cholinergic motor neurons in the C. elegans ventral nerve cord. The authors showed dual function of the terminal selector UNC-3 (Collier/Ebf) in directly promoting identity features of cholinergic motor neurons and indirectly preventing expression of terminal features of three other ventral cord neuron types (VD, VC, CA). Through an unbiased genetic screen, the authors identified the Hox protein LIN-39 (Scr/Dfd/Hox4-5) to be required for ectopic expression of VD and VC features in unc-3 mutants. In summary, the data presented in the paper supports the dual role of UNC-3: UNC-3 and LIN-39 directly co-activate terminal identity features of cholinergic motor neurons; UNC-3 antagonizes the LIN-39\'s ability of activating terminal features of alternative neuronal identities.
>
> The paper is well written. However, some points should be addressed or clarified.
>
> \- It has been previously shown that unc-3 and lin-39 in act synergistically to activate expression of cholinergic motor neuron terminal identity genes (Kratsios et al., 2017). This study identified a new role of unc-3 in antagonizing the LIN-39\'s function of activating terminal features of alternative neuronal identities. The authors should perform additional experiments to provide a mechanistic insight into how UNC-3 prevents LIN-39-mediated transcriptional switch for inducing expression of alternative identity features.

Our new set of experiments helped paint a clearer picture of the molecular mechanism underlying the dual role of UNC-3 and support the conclusion that LIN-39 is indeed the rate-limiting factor.

By using available LIN-39 ChIP-seq data, it is evident that LIN-39 directly binds to *cis*-regulatory elements of cholinergic MN identity genes (new Figure 5C), corroborating our genetic analysis. By performing ChIP-seq for LIN-39 in *unc-3* mutants, we found that LIN-39 binding is dramatically decreased to these gene loci (new Figure 5C). Our new RT-PCR data, in *unc-3* mutants, on these cholinergic MN terminal identity genes further corroborated the ChIP-seq data (new Figure 5---figure supplement 1). Together, these findings suggest that LIN-39 binding on cholinergic MN identity genes depends on UNC-3, raising the possibility that UNC-3 sequesters LIN-39 (or diverts LIN-39 activity) away from VD gene promoters. Supporting this scenario, ectopic expression of UNC-3 in VD neurons results in decreased expression of *lin-39*-dependent VD-specific markers (Figure 9C, Figure 9---figure supplement 2C).

In addition, we quantified the endogenous expression levels of *lin-39* and found it to be expressed at relatively low levels in cholinergic MNs (Figure 9A), further supporting the conclusion that LIN-39 is the rate-limiting factor. This conclusion is further supported by our gene dosage experiments for *unc-3* and *lin-39* (Figure 9B-C). For example, over-expression of LIN-39 in cholinergic MNs results in activation of VD-specific genes (Figure 9C). Together, our results suggest that the collaboration of UNC-3 with LIN-39 on cholinergic MN identity gene promoters exhausts the limited amount of LIN-39 in the cell and VD genes remain off. However, LIN-39 is released from cholinergic MN gene promoters in the absence of UNC-3 and activates VD genes.

Lastly, we now provide evidence that LIN-39 acts through distinct *cis*-regulatory elements to activate the same VD-specific gene (*oig-1*) in wild-type VD neurons versus VD-like neurons of *unc-3* mutants (new Figure 8, please also see our sixth response to reviewer \#2). We have revised the text to include these new findings (Results) and also discuss them in the context of literature mentioned by reviewers \#1 and \#2 (Introduction and Discussion).

> \- The authors showed data to indicate that lin-39 and unc-30 act in parallel to co-activate VD terminal identity genes. However, the authors also showed that ectopic expression of VD markers is not dependent on UNC-30. The contradictory results should be discussed. Does the data suggest that lin-39 acts with yet-to-be identified factor(s) to activate ectopic expression of VD features in unc-3 mutants?

We thank the reviewer for this comment, which helped us clarify, in the revised manuscript, the role of UNC-3 and LIN-39 in VD neurons. First, we now include ChIP-seq data for UNC-30 and LIN-39 that show direct binding for both proteins on the *cis*-regulatory region of VD terminal identity genes (*oig-1, ser-2, flp-11*) (new Figure 8, Figure 8---figure supplement 1). Second, both UNC-30 and LIN-39 positively control expression of VD genes; however, there are some noteworthy target gene-specific effects.

*oig-1*: UNC-30 is absolutely required for *oig-1* expression. LIN-39 is also required, but milder effects were observed in *lin-39* versus *unc-30* mutants (Figure 7B). The strong *unc-30* effects precluded us from building the double mutant.

*ser-2 and flp-11*: Mutants for *lin-39* show stronger effects on *ser-2* and *flp-11* expression when compared to *unc-30* mutants. Double *lin-39; unc-30* mutants showed additive effects, suggesting that LIN-39 and UNC-30 act in parallel to activate *ser-2* and *flp-11* expression (Figure 7B, Figure 4---figure supplement 2, panel E).

We note that the strongest possible alleles (putative null) were used for our analysis \[*lin-39(n1760), unc-30 (e191)*\].

Lastly, over-expression of LIN-39 in cholinergic motor neurons (which do not express *unc-30*) is sufficient to induce expression of the VD marker *ser-2* (Figure 9B).

The aforementioned genetic analyses together with the LIN-39 over-expression experiment indicate that LIN-39 is both necessary and sufficient for inducing *ser-2*. Hence, in *unc-3*-depleted MNs (which do not express *unc-30,* but do express *lin-39*) ectopic expression of *ser-2* is observed in *unc-3 mutants (*Figure 2A-B). This ectopic expression is dependent on *lin-39* as evident by our analysis of *unc-3; lin-39 (-)* double mutants (Figure 4D). However, the *ser-2* ectopic expression was not abolished in *unc-3; unc-30* double mutants (Figure 4---figure supplement 1, panel A), since *unc-30* is not expressed in cholinergic MNs. We now describe better these findings in the Results and with a new schematic in Figure 7F.
